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Abstract 
The transcriptional response to oxidative stress (OS) is involved in aging. 
As ROS-induced damages accumulate, cell senescence or apoptosis are 
triggered: these two mechanisms are implicated in the progressive 
physiological decay of the organism. Surprisingly, transcriptional pathways 
involved in OS-response play a role also in the balance between 
proliferation and differentiation during embryonic development. Recently, 
it has been discovered a transcriptional network that triggers cell cycle 
arrest in vitro upon OS. This pathway involves two well-known aging-
associated genes: p53, with its short isoform Δ40p53, and p66Shc. Here we 
propose the use of two complementary model organisms, Danio rerio 
(zebrafish) and Nothobranchius furzeri, to unravel the p53/p66Shc pathway 
in vivo. We report here that Δ40p53 and p66Shc are conserved in these 
species, partially recapitulating mammalian functions. Moreover, our 
findings about the spatial and temporal regulation of p66Shc expression 
during zebrafish embryogenesis suggest that p66Shc has a role in neural 
development. Furthermore, we generated the first genetic model of 
Δ40p53 ablation in zebrafish, exploiting the CRISPR/Cas9 technology. The 
structure of the p53 locus in mouse does not allow to selectively knock-out 
Δ40p53 without depleting also p53 activity. Our Δ40p53-/- zebrafish model 
shows the unique opportunity to characterize the biological functions of 
Δ40p53 isoform in physiological development in a context where p53 
expression is maintained unaltered. Finally, we provide preliminary data 
showing that Δ40p53 modulates in vivo p53-dependent transcriptional 
response to stress. 
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Introduction 
In the present thesis, we investigated the role of transcriptional response 
to oxidative stress (OS) in two, apparently opposite, physiological 
phenomena: aging and development. Several evidence shows that reactive 
oxygen species (ROS) take part in signalling pathways involved in the 
determination of aging and developmental processes. Among the various 
pathways, we focused on two genes participating in a recently discovered 
OS-induced transcriptional network that triggers cell cycle arrest in vitro: 
p53 (with its short isoform Δ40p53) and p66Shc. Our purpose is to dissect 
this pathway in vivo, taking advantage of two teleost fish as model 
organisms: Danio rerio and Nothobranchius furzeri.  
1. The role of oxidative stress response in aging 
Oxidative stress (OS), induced by reactive oxygen species (ROS), 
increases during lifespan and it is involved in the aging process. Aging is 
defined as the over-time increasing structural and functional decay of the 
organism, that leads to the increasing susceptibility to aging-related 
diseases (e.g. cancer, neurodegenerative diseases, metabolic syndrome), 
and ultimately death (López-Otín et al., 2013). According to the free radical 
theory of aging, postulated by Harman et al. in 1981, aging is strictly 
correlated to the accumulation of OS damage. ROS (e.g. hydrogen peroxide, 
superoxide anions and hydroxyl radicals) are physiologically produced by 
intracellular reactions, occurring in aerobic metabolism and involving 
oxygen as the final electron acceptor, although the environment is a major 
source of ROS. ROS generate reversible or irreversible modifications to 
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macromolecules, including DNA adducts, lipid peroxidation and protein 
carbonylation, impairing their functions. Defence mechanisms such as the 
activation of antioxidant enzymes (e.g. superoxide dismutase, catalase and 
glutathione peroxidase) have been positively selected to control 
intracellular ROS levels, but when ROS-induced damages accumulate, 
proliferation inhibition or apoptosis are triggered to avoid propagation of 
damaged cells (Giorgio et al., 2007). Nowadays, it is widely recognized that 
the permanent withdrawal of cells from cell cycle, known as cell 
senescence, is a biomarker of aging, since senescent cells accumulate in the 
aging organism. Tumour suppressor genes, such as p53, prevent 
uncontrolled proliferation and ultimately cancer, at the cost of impairing 
tissue replenishment and depleting the stem cell compartment (Campisi, 
2005). Increased apoptosis is another hallmark of aging. It has been shown 
that ROS, produced within the mitochondrion, induce damage to 
mitochondrial DNA (mtDNA) that leads to mitochondrial dysfunction, thus 
increasing ROS production and susceptibility to permeability transition pore 
(PTP) and apoptosis (Pollack and Leeuwenburgh, 2001). Several tissues 
exhibit cell loss during aging: skeletal muscle undergoes atrophy, called 
sarcopenia, that has been correlated with apoptosis, while other organs as 
heart and kidney show an increase of apoptotic markers (e.g. cytocrome c 
and activated caspase-3) during aging (Tower, 2015).  
According to these observations, it has been demonstrated that reduced 
OS is associated with delayed onset of aging phenotypes and lifespan 
prolongation in different long-lived mice models: (i) transgenic mice 
overexpressing mitochondrial catalase show reduced level of hydrogen 
peroxide and median and maximum lifespan extension (Shriner et al., 
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2005); (ii) mice deficient for one allele of the Insuline Growth Factor 1-
Receptor (IGF1-R) show both prolonged lifespan and resistance to OS 
(Holzenberger et al., 2003); (iii) the Ames dwarf mouse, that lacks growth 
hormone (GH), thyroid stimulating hormone (TSH) and prolactin, lives ~40-
60% longer and shows resistance to OS (Choski et al., 2011); (iv) mice 
overexpressing Klotho, a hormone that inhibits IGF1 signalling, are long-
living and show increased expression of manganese superoxide dismutase 
(Yamamoto et al., 2005), (v) p66Shc-/- mice (Migliaccio et al., 1999) and mice 
overexpressing a truncated isoform of p53, named p44, (Maier et al., 2004) 
show modulation of lifespan associated with peculiar OS response. These 
two models will be discussed later. 
The existence of several genetic models of aging demonstrates that 
aging might be determined by genes and that it cannot be merely 
considered the result of the progressive accumulation of environmental 
insults. Nevertheless, it has never been found a specific set of genes 
responsible for triggering organismal aging. This phenomenon is evidently 
associated to a complex interaction of genes that have been positively 
selected for their fundamental or positive role in the reproductive phase of 
life. According to the “antagonistic pleiotropy theory”, which is still object 
of debate, aging can be considered as the result of the collateral and 
detrimental effect of genes selected for their positive role in promoting 
health during development and youth (Kirkwood and Austad, 2000). 
2. The role of oxidative stress response in development 
Development can be considered as the opposite process of aging. 
Nevertheless, it has been demonstrated that genetic pathways involved in 
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development are also implicated in aging (Somel et al., 2010). In particular, 
it has been shown that ROS and OS response are important for normal 
development in mammals through cellular signalling and control of cell fate. 
A “free radical theory of development” (Allen and Balin, 1989) has been 
postulated some years later than the more famous Harman’s “free radical 
theory of aging”. This theory proposes that ROS function as “morphogens”. 
It is based on the observation that cells and tissues at various 
differentiation stages exhibit changes in intracellular ROS production and 
antioxidant defences, such as glutathione (GSH). This is produced at high 
level by poorly differentiated cells, favouring the maintenance of a reducing 
intracellular environment (Takahashi and Zeydel, 1982). More recently, it 
has been shown that intracellular ROS balance alters the functions of 
histone modifying enzyme during development, thus providing a 
mechanism through which ROS can drive gene expression and cell fate 
(Hitchler and Domann, 2007). Moreover, ROS contribute to trigger cellular 
differentiation after the initial high-rate proliferation driven by the reducing 
environment of the early post-implantation period in the mammalian 
embryo. Indeed, the balance of oxidative and reductive forces orchestrates 
signalling pathways in mammals (Dennery, 2007). In vitro, ROS are able to 
drive the cell fate of several cancerous and embryonic cell lines into various 
terminally differentiated cell types, from blood cells, to neurons and 
cardiomyocytes, by acting as signalling molecules and modulating the 
activity of several transcription factors. In contrast with these observations, 
it has been also proposed that ROS, produced at high levels by actively 
proliferating cells, are necessary to maintain uncontrolled proliferation of 
cancerous cells (Sauer et al., 2001). Finally, data produced by Dr. Migliaccio 
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at the European Institute of Oncology show that the aging protein p66Shc, 
that has been shown to produce hydrogen peroxide and will be discussed in 
detail, is involved in the maintenance of the stem cell compartment in the 
mammary gland: mice lacking p66Shc show an increased capacity in self-
renewal of proliferating mammary stem cells during aging, suggesting that 
p66Shc might be involved in asymmetrical cell division (Montariello et al., 
manuscript in preparation). Even though the molecular mechanism 
underlying the increased self-renewal capacity of the aging mammary gland 
in p66Shc-/- mice has to be elucidated, it is tempting to hypothesize that ROS 
produced by p66Shc participate in cell fate decision. This hypothesis can also 
link the role of p66Shc in aging with its role in development, explaining why a 
gene that shows detrimental functions in adult life has been maintained 
throughout evolution.   
If the physiological role of ROS as signalling molecules in development 
and their function in controlling the switching from proliferation to 
differentiation is still to be investigated in depth, it is instead clear that 
abnormal exposure to ROS is associated with a large variety of birth defects. 
ROS are powerful teratogens: the teratogenic effect of substances such as 
ethanol (Peng et al., 2005) and thalidomide (Parman et al., 1999) resides in 
their ability to produce free radicals. In this context, it is clear the 
importance of genes involved in OS response during development: as an 
example, it has been demonstrated that the teratogenic effects of ROS are 
increased in a p53-/- genetic context (Wells et al., 2005). Recent data show 
that also zebrafish is responsive to OS during development. Moreover, the 
transcriptional response induced by OS is substantially conserved between 
fish and mammals (Hahn et al., 2014).  
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Although the role of ROS in development has not been extensively 
studied, a growing bulk of evidence shows that the same aging-associated 
genes, involved in ROS response, can play a role also in development. We 
propose here the combined study of two well-known aging associated 
genes - p53, in particular its short isoform Δ40p53, and p66Shc - in 
development and aging. We also propose the use of two animal models 
that, according to their characteristics, represent the best model for 
research on development or aging, respectively: Danio rerio, also known as 
zebrafish, and the short-living vertebrate Nothobranchius furzeri. In the 
following paragraphs, it will be discussed the state of the art on our chosen 
genes and models. 
3. Oxidative stress-related genes in development and aging: 
the case of p53 and p66Shc 
3.1 p66Shc 
p66Shc is the longest isoform encoded by the shc1 locus, whose discover 
dates back to 1992. The shc1 gene was initially characterized as a novel 
proto-oncogene, encoding for two isoforms, namely p52Shc and p46Shc, 
involved in Ras signalling. These two isoforms, translated from the same 
mRNA through the usage of alternative ATGs, are phosphorylated by active 
tyrosine kinase receptors. Upon phosphorylation, p52Shc and p46Shc function 
as adaptor proteins, recruiting to the plasma membrane the GRB2-SOS 
complex, which mediates the activation of the Ras small GTPase, thus 
initiating the MAPK (Mitogen-Activated Protein Kinase) cascade (Pelicci et 
al., 1992). 
Unravelling the p53/p66Shc pathway in vivo  
 
9 
 
The third isoform, p66Shc, is translated from a different mRNA, expressed 
by its own promoter. p66Shc contains the entire p52Shc/p46Shc sequence plus 
an additional N-terminal region (Ventura et al., 2002). Although p66Shc is 
phosphorylated by active tyrosine kinase receptors, as the shorter isoforms 
encoded by shc1, it is not involved in Ras signalling. Therefore, p66Shc, 
contrary to p52Shc/p46Shc does not contribute to stimulate proliferation 
(Migliaccio et al., 1997).  
p66Shc shares with p52Shc/p46Shc, from N-terminal to C-terminal, the PTB 
(Phospho-Tyrosine Binding) domain, the CH1 (Collagen Homologous 1) 
domain and the SH2 (Src Homologous) domain. Its unique amino-terminal 
domain, named CH2 (Collagen Homologous 2), is crucial to differentiate the 
role of p66Shc from the shorter isoforms. In cultured mouse embryonic 
fibroblasts (MEFs), p66Shc is rapidly phosphorylated on a serine residue 
present in its unique CH2 domain, upon treatment with hydrogen peroxide 
or UV, leading to its activation (Migliaccio et al., 1999; Figure 1). 
Figure 1. Modular domain organisation of Shc isoforms. p66Shc, p52Shc and p46Shc 
share, from C-terminal to N-terminal, SH2, CH1 and PTB domains. p66Shc shows a 
unique N-terminal domain, CH2, where the serine residue phosphorylated upon 
OS is located. The EEW is the amino-acidic core of the Cytochrome c binding 
domain, (CB), present in p66Shc and p52Shc, but absent in p46Shc (Atlas of Genetics 
and Cytogenetics in Oncology and Haematology). 
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At basal conditions, p66Shc is located within the intermembrane space of 
the mitochondrion, where it is bound to the TIM/TOM importing complex 
and to chaperonine Hsp70. Cellular stresses stimulate the release of p66Shc 
from this complex and promote its binding to the Cytochrome c (Cyt c). The 
Cyt c Binding Domain (CBD; Figure 1) has been mapped between the CH2 
and the PTB domain. Bound to reduced Cyt c, p66Shc subtracs electrons 
from ETC to generate hydrogen peroxide from molecular oxygen. This event 
induces the opening of the Permeability Transition Pore (PTP) that triggers 
mitochondrion swelling and the release of Cyt c from the outer membrane, 
leading to the execution of apoptosis. The crucial role of p66Shc in the 
mitochondrial apoptosis pathway has been demonstrated both in vitro, 
where p66Shc oxidizes Cyt c, triggering mitochondrial swelling, and in vivo, 
taking advantage of the p66Shc-/- mouse model (Giorgio et al., 2005; Figure 
2). 
 
Figure 2. Model of p66Shc redox activity during mitochondrial apoptosis. Pro-
apoptotic signals induce release of p66Shc from a putative inhibitory complex. 
Active p66Shc oxidises reduced Cyt c (red) and catalyses the reduction of O2 to 
H2O2. PTP opening by H2O2 leads to mitochondrial swelling and apoptosis (Giorgio 
et al., 2005). 
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p66Shc in aging 
The p66Shc-/- mouse model, generated in 1999, is a genetic model of 
healthy aging. The deletion of p66Shc improves general health in the aging 
mouse and it is associated with an elongation in lifespan, although this 
datum is still controversial (Migliaccio et al., 1999; Ramsey et al., 2014). In 
vivo, the deletion of p66Shc is associated with: (i) increased resistance to OS-
induced apoptosis upon treatment with paraquat, a potent pro-oxidant 
(Migliaccio et al., 1999); (ii) reduced apoptosis and tissue damage induced 
by acute ischemia (Zaccagnini et al., 2004); (iii) reduced nephropathies in a 
mouse model of diabetes (Menini et al., 2006); (iv) amelioration of the age-
dependent decrease of endothelial functions (Francia et al., 2004); (v) 
amelioration of liver conditions in a mouse model of ethanol-induced 
hepatic steatosis (Koch et al., 2008); (vi) amelioration of cognitive functions 
in a mouse model of Alzheimer disease (Derungs et al., 2016); (vii) partial 
recovery of fertility, internal organ size and body weight in the progeric 
mouse model deficient for the Telomerase RNA component (TERC; Giorgio 
et al., 2016).  
Although the molecular mechanisms underlying all the beneficial effects 
of p66Shc deletion in mice are still to be elucidated, it has been 
demonstrated that p66Shc, by increasing intracellular ROS levels, 
participates in various pathway known for being involved in aging. In 
particular, it has been shown that p66Shc has a key role in the insulin 
pathway: insulin stimulation induces phosphorylation of p66Shc and 
production of hydrogen peroxide. H2O2 in turn regulates the insulin 
signalling: in adipocytes derived from p66Shc-/- mice, insulin-dependent 
Protein Kinase B/AKT activation results attenuated and also FOXO 
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(Forkhead Box O) activity is impaired. These findings explain the reason why 
p66Shc-/- mice exhibit reduced fat accumulation and hepatic steatosis 
(Berniakovich et al., 2008).  
A consistent body of evidence demonstrates also that p66Shc is regulated 
at epigenetic level: for example, the decreased epithelial dysfunctions 
associated with p66Shc deletion are mediated by (i) low-density lipoprotein 
cholesterol, that stimulates human p66Shc expression (Kim et al., 2012); (ii) 
SIRT1, that represses p66Shc in a model of hyperglycaemia-induced 
endothelial dysfunction, conferring an amelioration of the phenotype (Zhou 
et al., 2011), and (iii) homocysteine, which promotes p66Shc expression (Kim 
et al., 2011). 
p66Shc in development 
The fact that the ablation of p66Shc is associated with an amelioration of 
the aging phenotype in laboratory mice and in mouse models of human 
aging-associated diseases suggests that p66Shc has been evolutionary 
maintained for its positive functions exerted in development and/or 
reproductive phase of life. What these functions are is still unclear, even if it 
is possible to speculate that they could be related to p66Shc redox activity. 
Indeed, it is known that ROS play an important role in developmental 
processes such as cell differentiation (Dennery et al., 2007). On the other 
hand, it is evident as well that p66Shc is not necessary in embryogenesis, 
because p66Shc-/- mice are viable, p66Shc-/- embryos are not counterselected 
during gestation and no significant incidence of developmental 
abnormalities has been recorded (personal communication by Dr Giorgio). 
Unravelling the p53/p66Shc pathway in vivo  
 
13 
 
For all these reasons, few efforts have been focused on understanding the 
role of p66Shc in development.  
Nevertheless, there are evidence suggesting a function for p66Shc in 
neurogenesis. The expression regulation of the three isoforms of the shc1 
gene was investigated in 1997 through western blot and in situ 
hybridization in the brain of the developing mouse: all the three isoforms 
are exclusively expressed within the ventricular zone, the area were 
immature neuroblasts proliferate, being p66Shc the less represented 
isoform. On the contrary, in the post-natal adult brain the expression of Shc 
isoforms was detected only in the olfactory epithelium, where neuronal 
self-renewal occurs also in adulthood. Considering that p66Shc, contrary to 
the other isoforms, is not involved in proliferation (Migliaccio et al., 1999), 
these findings lead to the intriguing hypothesis that p66Shc, in concert with 
p52Shc/p46Shc, has the role of orchestrating cell fate in neurogenesis (Conti 
et al., 1997). According with these observations, it has been found that in 
human and murine embryonic stem cells the overexpression of p66Shc 
anticipates the loss of pluripotency and induces the acquisition of a 
neuronal fate, through the regulation of the Wnt/β-catenin pathway 
(Papadimou et al., 2009). These data suggest that p66Shc might have a role 
in development and in particular in neuronal differentiation. Finally, it has 
been demonstrated that p66Shc has a role in metabolic adaptation: p66Shc-/- 
mice have been studied in a natural environment, subjected to food 
competition and low temperatures. In these conditions, p66Shc deletion 
resulted deleterious: as previously mentioned, p66Shc is involved in fat 
accumulation and energy metabolism; p66Shc-/- mice exposed to low 
temperatures resulted counterselected due to their inability to accumulate 
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fat, when food is not constantly available as it is in captivity. Moreover, it 
has been found a reduction in fertility under stressed conditions and in 
maternal cares (Giorgio et al., 2012). Taken together, these findings might 
explain the fact that p66Shc plays a positive role in adaptation, that becomes 
deleterious when mice are kept in controlled conditions such as absence of 
competition, constant warm temperature and food availability.  
3.2 p53 
Known for being the “guardian of the genome”, p53 is the most 
frequently mutated protein in human cancer and one of the most 
intensively studied gene (Vogelstein et al., 2010). Nevertheless, the 
complete understanding of its numerous functions is still far from being 
achieved.  
p53 is a transcription factor that acts as a tetramer in response to 
different stresses and it is a key regulator of DNA and protein damage 
response. In adult tissues, normally, p53 levels are very low: stress signals 
induce post-transcriptional modifications, such as acetylation, 
phosphorylation and sumoylation to specific amino-acidic residues, that 
stabilize p53 protein, avoiding its degradation and promoting its 
tetramerization (Bode and Dong, 2004).  
p53 is active mainly in cell cycle control and different levels of stress and 
damage to macromolecules can trigger different p53-dependent 
transcriptional responses. They can lead to: (i) transient cell cycle arrest, 
through the activation of cyclin inhibitors such as p21, when damages are 
successfully repaired and the cell can recover its functions; (ii) apoptosis, 
through the activation of pro-apoptotic genes such as bax and puma and 
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negative regulation of anti-apoptotic genes such as bcl-2; (iii) permanent 
cell cycle arrest, known as cell senescence. Apoptosis and cell senescence 
are mainly chosen when damages to macromolecules cannot be repaired, 
to avoid propagation of damaged, potentially cancerous cells (Bargonetti 
and Manfredi, 2002).  
However, it is still unclear how a single gene can orchestrate such a wide 
range of different pathways in response to a plethora of signals. This 
complexity can be explained by the finding that the p53 gene encodes 
several p53 isoforms through the use of internal promoters, internal 
ribosomal entry site (IRES) and alternative splicing. These mechanisms are 
responsible for the production of the 12 p53 isoforms already identified in 
humans, that are distinguishable for the presence of different domains and 
specifically regulated. p53 isoforms are the result of the combinations 
among different N-terminal regions, that lack the entire Transcription 
Activation Domain (TAD) or even part of the DNA Binding Domain (DBD), 
and different C-terminal domains, where the Oligomerization Domain (OD) 
can be replaced by two different amino-acidic sequences. This surprising 
variability in p53 isoforms, that can or cannot associate each other or with 
canonical p53, that are specifically regulated among tissues and produced 
in response to different stimuli, explain why a single gene can be 
responsible for such a variety of functions (Figure 3; Khoury and Bourdon, 
2011).  
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p53 in aging 
Considering that apoptosis and cell senescence are known to be involved 
in aging, it is clear that p53 is active also in the regulation of aging 
processes: this makes p53 both the major defence against cancer and the 
road that leads to aging. The role of p53 in aging is demonstrated by several 
studies in mouse models of longevity. The first evidence that links 
genetically p53 and aging was obtained in a mouse model that expresses a 
truncated p53 protein, named p53m. In presence of the wild-type allele, 
p53m confers an increase in the tumour suppressor activity exerted by p53, 
at the cost of a reduction in lifespan associated with early onset of aging 
phenotypes, such as general loss of body mass, atrophy of internal organs, 
Figure 3. Human p53 protein isoforms. The canonical p53 protein contains a TAD 
(blue), a proline-rich domain (PXXP, purple), a DNA-binding domain (DBD, orange) 
and an OD (green) that encompasses a nuclear localization domain (NLS, green) 
and five regions conserved through evolution (I–V in grey boxes). Compared with 
p53, the Δ40p53 isoforms lack the first TAD, whereas the Δ133p53 and Δ160p53 
isoforms lack the entire TAD and parts of the DBD. At the C-terminal, the α-
peptide corresponds to the OD that can be replaced by new residues, the β- and 
γ-peptides (brown; modified from Khoury and Bourdon, 2011). 
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osteoporosis and kyphosis. The p53m allele has a deletion of the first six 
exons of the p53 gene that leads to the loss of the two trans-activation 
domains. This determines the inability of p53m to exert a role of 
transcription factor per se, but also it leads to p53 stabilization due to the 
loss of the Mouse Double Minute 2 (MDM2) binding domain. MDM2 is the 
ubiquitin ligase that triggers p53 degradation. Moreover, p53m retains the 
ability to form tetramers with p53 due to the presence of an unaltered C-
terminal oligomerization domain. As a consequence, the role of p53m in 
conferring a premature aging phenotype is determined by the presence of a 
wild-type p53 and it is the result of an increase in p53 activity and 
modulation of its transcriptional response. This demonstrates that p53 
stabilization leads to cancer resistance at the cost of premature aging and 
reduced lifespan, probably due to the depletion of stem cell compartment 
and compromised tissue homeostasis (Tyner et al., 2002).  
In contrast to this, another study in a different genetic model that 
harbours an extra copy of the entire p53 gene, and named “super-p53”, 
shows a completely different scenario. These mice are characterized by an 
increased resistance to cancer but are not subjected to premature aging or 
reduced lifespan. In this case, p53 is not stabilized and its activity is 
maintained at a basal level, but it results increased when p53 stabilization is 
stimulated by damage to DNA. Therefore, although the p53 pro-apoptotic 
response is enhanced upon stress exposure, the “super-p53” mice have a 
normal lifespan and do not show signs of premature aging due to 
premature loss of tissue homeostasis (Garcia-Cao et al., 2002).  
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In conclusion, p53 plays a complex role in lifespan and aging modulation: 
when p53 activity in enhanced, but the mechanisms ensuring a normal 
regulation of its turn-over are maintained, p53 promotes longevity. On the 
contrary, when it is constitutively active, p53 promotes aging without an 
increase in cancer susceptibility. Therefore, the p53-dependent 
transcriptional response is fine-tuned to avoid proliferation of damaged, 
potentially cancerous, cells but also to avoid the loss of stem cell 
compartments and preserve tissue homeostasis (Figure 4; Feng et al., 2011; 
Reinhardt and Schumacher, 2012).  
 
p53 in development 
In 1992, it was generated a genetic model of p53 ablation: p53-/- mice 
develop normally, such as p66Shc-/- mice, suggesting that p53 has not a 
fundamental role in development (Donehower et al., 1992). Nevertheless, a 
Figure 4. Activation modes of p53 
determine the physiological 
outcome. (a) In wild-type cells, p53 
exhibits low basal activity. Only 
upon stress signals, p53 is activated 
to prevent oncogenic 
transformation of cells. (b) 
Increased p53 activity, induced by 
the expression of short p53 
isoforms, promotes cancer 
resistance, at the cost of impaired 
tissue regeneration and accelerated 
aging. (c) Low basal levels of p53, 
together with strong p53 activation 
only in response to stress, lead to 
cancer protection and normal 
lifespan (Reinhardt and 
Schumacher, 2012). 
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report of some years after demonstrated that a significant proportion of 
female p53-/- mice die during embryogenesis or in the period between birth 
and weaning. p53-/- female embryos fail to complete the normal 
development of neural tube and result affected of exencephaly, suggesting 
that p53 may play a role in neural development (Armstrong et al., 1995). 
Moreover, it has been shown that (i) constitutively active p53 is associated 
with embryonic lethality; (ii) a decrease in p53 expression levels leads to 
increased foetal lethality in embryos treated with teratogens (Choi and 
Donehower, 1999); (iii) p53 induces differentiation of mouse Embryonic 
Stem Cells (mESC) by suppressing nanog expression (Lin et al., 2005); (iv) 
p53 plays a regulatory role in directing primary neurons, oligodendrocytes, 
and PC12 cells toward either differentiation or apoptosis in vitro (Eizenberg 
et al., 1996). Altogether, these findings demonstrate that p53 could be 
involved in different developmental processes, even though p53 is not 
strictly necessary to complete development in mammals and, in absence of 
environmental stresses, other genes can compensate the lack of p53.  
3.3 Δ40p53, or p44, a short isoform of p53 
In our research, we focus our attention on a short isoform of p53, named 
Δ40p53, encoded by the p53 gene. In mammals, the canonical p53 
transcript encodes Δ40p53 thanks to an IRES located in exon 4 (Courtois et 
al., 2002), even if it has been reported an alternative splicing mechanism for 
Δ40p53 production in human (Ghosh et al., 2004). This isoform has a mass 
of about 44KDa in the mouse and 47KDa in human, and thus it will be 
referred to as “p44” hereafter. p44 is a N-terminally truncated isoform that 
lacks the first TAD, retaining the second TAD and all the p53 functional 
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domains and maintaining the ability to form oligomers with the canonical 
p53 protein. Together with the first TAD, p44 lacks the MDM2 binding 
domain: it has been demonstrated that p44 is unable to complex with 
MDM2 avoiding ubiquitination and degradation (Yin et al., 2002).  
p44 expression depends on p53 post-transcriptional regulation: the 
canonical p53 and its short isoform share the same mRNA. Mouse 
embryonic fibroblast infected with p53 cDNA express both full-length p53 
and its short isoform, while the same cDNA mutated at codon 40 is unable 
to produce the p44 protein. More in detail, the choice of the initiation site 
of translation depends on the interaction between p53 and its mRNA: the 
N-terminal domain of p53 binds a stem-loop structure located in the 5’UTR 
of its own mRNA. This interaction blocks p53 translation and causes the 
ribosome to choose the second IRES located in exon 4, leading to p44 
translation. The production of p44 is regulated also by MDM2 that interacts 
with the N-terminal domain of p53, avoiding the binding of p53 protein 
with its own mRNA and leading to p53 translation (Yin et al., 2002; 
Ungewitter and Scrable, 2010).  
The p44 isoform determines p53 functions: due to the lack of the first 
TAD, it is widely accepted that p44 is not able to drive by itself the 
transcription of p53 target genes (Courtois et al., 2002). Nevertheless, there 
is also evidence that p44 can be considered an autonomous transcription 
factor (Phang et al., 2015). However, it is known that p44, thanks to its 
intact oligomerization domain, has the ability to form oligomers with p53, 
determining its localization and fine-tuning its transcriptional activity: (i) the 
human p44 ortholog localizes into the cytoplasm and its overexpression 
drives p53 localization from the nucleus to the cytoplasm (Ghosh et al., 
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2004); (ii) endoplasmic reticulum (ER) stress promotes the formation of 
p44/p53 oligomers leading to G2 arrest of the cell cycle (Bourougaa et al., 
2010); (iii) the human p44 ortholog accumulates in response to genotoxic 
stress, modulating p53 post translational modification pattern and 
enhancing p21 expression (Powell et al., 2008). The formation of oligomers 
between p44 and p53 depends on the delicate equilibrium between these 
two isoforms: high levels of p44 induce the formation of p44 
homotetramers, compromising p53 functions. When p44 and p53 form 
heterotetramers (where the p53:p44 ratio is variable), this configuration is 
more stable than p53 homotetramers, because p44 lacks the MDM2 
binding domain: this results in the modulation of p53 transcriptional activity 
(Ungewitter and Scrable, 2010).  
p44 in aging  
The role of p44 in aging has been demonstrated with the production of a 
mouse genetic model that overexpresses p44, named Tgp44: in this model, 
full-length p53 expression is maintained. The Tgp44 mice show premature 
signs of aging: as early as 4-month old, these mice show osteoporosis, 
kyphosis, infertility and reduced body size, and they die within the first year 
of age, without developing cancer. It has been demonstrated that the 
reduced susceptibility to cancer observed in these mice depends on the 
presence of p53, given the fact that p53-/- mice overexpressing p44 are 
susceptible to cancer as p53-/- mice. Cultured cells derived from adult Tgp44 
mice exhibit enhanced p21 expression and increased levels of IFG-1 
hormone and its receptor IGF-1R in mitotically active tissues. This finding 
indirectly demonstrates the fact that an altered p53:p44 ratio leads to a 
modification of the normal p53-dependent activity. This shows that, as in 
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invertebrate models like Caenorhabditis elegans and Drosophila 
melanogaster, the aging process is regulated by the insulin/IGF-1 signalling 
pathway also in mammals, where it is also regulated by p53 and particularly 
by its short isoform p44 (Maier et al., 2004).  
p44 in development 
Strikingly, it has been observed that p44 plays also an important role in 
development: in mESCs derived from wild-type mice, p53 and p44 levels are 
high and decrease with the loss of pluripotency. High levels of p44 are 
observed in embryos immediately after implantation, while full-length p53 
is not expressed yet: therefore, p44 has been considered an embryonic 
isoform of p53, whose expression is high in pluripotent stem cells, 
decreasing as differentiation occurs. In mESCs, the downregulation of p44 
expression leads to growth arrest because stem cells enter the G0/G1 
phase, as it happens in terminally differentiated cells. This phenomenon is 
accompanied by a drastic decrease in the expression of two stem cell 
markers, nanog and oct4. On the contrary, mESCs derived from Tgp44 mice 
show a higher rate of proliferation than wild-type ones. These findings 
suggest that the dosage of p44 plays a crucial role in early mammalian 
development, in particular for the switch from pluripotency to 
differentiation. Also in development, p44 functions in concert with p53: 
these two proteins form heterodimers not only in somatic cells, but also in 
mESCs, where p44 evidently modulates p53 stability and transcriptional 
activity. More in detail, by the comparison of expression levels of several 
p53 targets in WT-mESCs and Tgp44-mESCs, it has been revealed that p44 
interferes with the capacity of p53 to bind specific promoters, as those of 
nanog and ifg-1R. This leads to the overexpression of these genes. On these 
Unravelling the p53/p66Shc pathway in vivo  
 
23 
 
bases, it is evident that the main function of p44 in the early stages of 
embryogenesis is to suppress p53 activity by preventing the trans-
suppression of factors such as Nanog and IGF-1R, to preserve the 
pluripotency. When levels of p44 decrease, the negative regulation of p53 
decreases as well, and ESCs begin to differentiate (Ungewitter and Scrable, 
2010).  
3.4 A link between p53/p44, p66Shc and oxidative stress 
A recent work demonstrated that the p44 isoform takes part in a 
pathway that involves also the p66Shc redox protein. In response to OS, in 
mouse embryonic fibroblasts (MEFs) it is activated a p53/p44-p66Shc 
dependent transcriptional program that is abrogated in p66Shc-/- mice. This 
transcriptional response leads to the repression of ~200 genes responsible 
for cell cycle progression between G2 and M phases and mitotic spindle 
checkpoint. These genes are normally downregulated during physiological 
aging in various tissues: their downregulation is responsible for the 
accumulation of senescent cells, a well-known hallmark of aging. These 
genes are downregulated also upon genotoxic stress (GS), but 
independently from p66Shc: indeed, in MEFs derived from p66Shc-/- mice 
treated with a potent mutagen, doxorubicin, the GS-dependent 
transcriptional response is conserved. On the contrary, when the same cells 
are treated with hydrogen peroxide, this transcriptional response is lost. 
Importantly, OS is not only cause of DNA damage but causes damage to all 
macromolecules. This datum demonstrates that the transcriptional 
response to OS is p66Shc-dependent.  
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Moreover, in MEFs derived from p53-/- mice, the transcriptional response 
is totally abrogated upon both OS and GS. In summary, the downregulation 
of the 200 genes involved in cell cycle progression is (i) p53-dependent; (ii) 
p66Shc-independent in case of GS; (iii) p66Shc-dependent in case of OS and 
protein/lipid damage. Notably, in p66Shc-/- mice, part of these genes is less 
downregulated in aging than in wild-type mice. p66Shc-/- mice are a model of 
healthy aging also because they accumulate less senescent cells, thanks to 
the abrogation of the p66Shc-dependent transcriptional response to OS that 
leads to cell cycle arrest.  
Furthermore, it is evident that p53 acts in response to stress in 
cooperation with different partners: not only p66Shc orchestrates p53-
dependent transcriptional response to OS, but also p44. Indeed, in MEFs 
derived from Tgp44 mice, the p53/p66Shc-dependent downregulation of 
G2/M transition genes is higher than in WT-MEFs. Additionally, in MEFs 
derived from Tgp44/p66Shc-/- mice, the transcriptional response to OS is 
abrogated, while it is maintained in case of GS. Therefore, the effect of 
p66Shc is epistatic to p44.  
Finally, it has been observed that the deletion of p66Shc partially recovers 
the progeroid phenotype of Tgp44 mice. In conclusion, this work proposes 
that (i) p53 acts through different partners in response to different stress 
agents; (ii) the tumour suppression functions of p53 are exerted 
independently from p66Shc and p44; (iii) the role of p53 in aging is linked to 
the aging proteins p44 and p66Shc (Figure 5; Gambino et al., 2013). 
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4. The models: Danio rerio (zebrafish) and the short-living 
killifish Nothobranchius furzeri 
As the final goal of this study is to investigate the role of the p53/p66Shc 
pathway in aging and development, we carefully chose the most suitable 
models for our research. 
Invertebrate models such as Drosophila melanogaster and 
Caenorhabditis elegans have a single homolog of the p53-family genes. p53-
family is composed by p53 and its isoforms, p63 and p73 with their 
Figure 5. p53 exerts its double role in tumour suppression and aging through 
distinct pathways. Oxidative stress causes protein damage and activates a 
specific p53-dependent transcriptional response in concert with its short isoform 
p44 and p66Shc. The downregulation of G2/M transition genes leads to cell 
senescence, apoptosis and ultimately aging. On the other hand, DNA damage 
stimulates p53 activity independently from p66Shc and p44. Different genes are 
involved in DNA damage response and they are responsible for tumour 
suppression (Migliaccio et al., 2013).  
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isoforms. In worms and insects, the single p53-family homolog is more 
closely related to p63/p73 than p53 and it can be considered an ancestor of 
the entire p53-family. It is with cartilaginous fish that can be found two p53 
paralogs: a p53 gene and a hybrid p63/p73 gene. Teleost fish, such as Danio 
rerio and Nothobranchius furzeri, have clear orthologs of p53, p63 and p73 
genes (Belyi et al. 2010). Thus, considering also that p53 key amino-acidic 
residues are substantially conserved between fish and mammals, fish 
represent a good compromise among vertebrate and invertebrate models 
to study in vivo p53 functions.   
p66Shc is instead a vertebrate protein. In D. melanogaster and C. elegans, 
two different Shc-like coding sequences can be found: they show a modular 
organization in which the PTB domain is followed by SH2 domain, but the 
CH1 and CH2 domains are not present (Luzi et al., 2000). It is only with 
teleost fish that the p66Shc gene is clearly recognizable. In fish, the modular 
organization of p66Shc is conserved: in particular, the key amino-acidic 
residues and the Cytochrome c binding domain, fundamental for p66Shc to 
exert its function as a redox protein, are present. Thus, fish represent the 
lowest model in evolution to study in vivo p66Shc functions.   
Since our purpose is to investigate the role of these genes in 
development and aging, mice do not represent the best model, even if they 
are closer to humans: (i) mouse embryos develop in utero, thus whenever it 
is necessary to analyse them, the mother has to be sacrificed; (ii) embryo 
development lasts 3 weeks; (iii) a female mouse gives birth to only 6-12 
pups per month; (iv) mice can live more than 2 years in captivity. Finally, it 
is important also to point out that both aging and development are 
systemic processes that involve the whole organism and cannot be properly 
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surrogated by in vitro culture. For all these reasons, we chose teleost fish as 
a model for this study: in the following paragraphs, it will be discussed the 
choice of two different species (Danio rerio and Nothobranchius furzeri) and 
the state of the art about p53/p44 and p66Shc in our models.  
4.1 Danio rerio (zebrafish) 
An overview on the available technologies 
Danio rerio, hereafter referred to as “zebrafish”, is nowadays widely 
considered the best model for the developmental biology and genetic 
studies. The zebrafish is a tropical fish native to South-East Asia; since 
1960s, it has become increasingly important in scientific research because 
of its attractive features: (i) embryo development is extremely conserved in 
vertebrates and most of the genetic programmes involved are conserved 
among species; (ii) zebrafish females can lie a substantial number of eggs 
(200-300) every week; (iii) zebrafish embryos are completely transparent 
and develop externally – they are maintained in controlled conditions and 
can be checked whenever needed; (iv) embryos complete organogenesis 
within the third day post fertilization and begin to feed autonomously 
within the sixth day – this makes zebrafish one of the most rapidly 
developing vertebrates (Kimmel et al., 1995). Moreover, the zebrafish 
genome, which consists of 1.5 billion base-pairs (a half than human 
genome) and 26 thousand protein-coding genes (more than ever previously 
sequenced vertebrate) has been published in 2013: it appears that 71% of 
human proteins have an obvious ortholog in zebrafish (Howe et al, 2013).  
Since zebrafish has been used in scientific research for more than 50 
years, a wide range of techniques and protocols have been standardized 
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among laboratories and universally accepted by the scientific community. 
Toxicological studies have been successfully carried out in zebrafish 
embryos, as they can be exposed and subsequently analysed for their 
phenotype, physiology, metabolomics, transcriptomics, etc., by simply 
dissolving compounds in fish water: a wide range of compounds, dilutions 
and combinations can be tested altogether, taking advantage of the 
zebrafish high fecundity; for the same reason, it is considered a valuable 
tool for pharmacology and drug discovery (MacRae and Peterson, 2015). 
Genetic engineering techniques have been successfully applied in zebrafish: 
transient modulation of gene expression is extremely feasible. It is possible 
to microinject in vitro-synthetized mRNA molecules (“gain of function” 
experiments) or antisense oligonucleotides (named Morpholinos – “loss of 
function” experiments) in the one-cell stage embryo, so that the chosen 
gene results overexpressed or downregulated in all the developing embryo 
for the first 3-4 days of development, until the microinjected molecules are 
too much diluted or degraded (Rosen et al., 2009). Most importantly, the 
production of transgenic and knock-in lines, which allows the study of gene 
expression patterns and aberrant expression of wild-type and mutated 
genes, are routinely in zebrafish: a wide range of inducible and tissue-
specific systems are available. On the other hand, gene knock-out has been 
challenging for years, since the use of zinc-finger nucleases and TALENs 
(Transcription Activator-Like Effector Nucleases) is particularly expensive: 
the arrival of the CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeat)-Cas9 technology, which is extremely efficient and cheap, has led to 
revolution in the field of genetic manipulation in zebrafish. Since its first 
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application in 2013, hundreds of knock-out zebrafish lines have been 
generated (Hwang et al., 2013; Li et al., 2016). 
An overview on embryonic development 
Zebrafish embryonic development has been extensively investigated by 
Kimmel and colleagues in the early 1990s: their works are still the most 
exhaustive in literature; it will be referred to Kimmel et al., 1995 for all the 
information provided below.  
Zebrafish development can be divided into seven periods, from 
fertilization of the egg to the hatching of the larva. Each period will be 
briefly discussed below: 
1. Zygote period (0 – 45’). Zebrafish egg is 0.7mm in diameter and 
telolecithal: 2/3 of its volume consists of yolk, the substance that 
provide nutrients to the developing embryo on top of it (animal pole). 
Microtubule arrays extend along the animal-vegetal axis to the 
vegetal pole, maintaining a contact between the blastomeres and the 
yolk cell.  The first period starts with fertilization and ends with the 
formation of the first cleavage furrow. The cleavage occurs only in the 
blastodisc, the portion of yolk-free cytoplasm at the animal cap, that 
becomes visible at the end of this stage (Figure 6.a).  
2. Cleavage period (45’ – 2h and 15’). The divisions occur at 15-minute 
intervals and are defined meroblastic, because the blastodisc is 
divided only partially and the resulting blastomeres are 
interconnected by cytoplasmic bridges until the 8-cell stage. In this 
period, six synchronic divisions occur: at the end, the embryo counts 
64 cells that form the blastoderm at the animal pole (Figure 6.b-g). 
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3. Blastula period (2h and 15’ – 5h and 15’). This period starts from the 
128-cell stage to the beginning of gastrulation. The first important 
event occurs at cycle 10 when the mid-blastula transition begins: the 
zygotic genome is now actively transcribed; cell divisions becomes 
asynchronous and cells acquire mobility. The second important event 
is the formation of the yolk syncytial layer: the inner cell layer of the 
blastoderm fuses with the yolk and divide forming extraembryonic 
tissues. When the epiboly begins, the blastodisc and the yolk syncytial 
layer move on the surface of the yolk to envelop it. This period ends 
when the cells of the blastoderm have covered the 30% of the yolk-
cell (Figure 6.h-p). 
4. Gastrula period (5h and 15’ – 10h). Gastrulation begins when epiboly 
has reached the 50%. At this stage, a thickening is visible throughout 
the margin of the blastoderm: it is called “germ ring” and consists of a 
superficial layer, the epiblast, and an inner layer, the hypoblast. 
Convergence movements leads to the formation of a localized 
thickening called “embryonic shield”. This is the zebrafish embryo 
organizer because it is able, when transplanted to a host embryo, to 
organize a secondary axis. In this period, the three germ layers 
distinguish each other; at the end of the movements of convergence 
and extension, the presumptive map of the embryo can be drawn. 
When gastrulation ends, the mesoderm (hypoblast) can be 
distinguished in axial mesoderm (notochord) and paraxial mesoderm 
(eyes, jaws, gills and somites), while the dorsal epiblast forms the 
neural keel (Figure 6.q-u). 
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5. Segmentation period (10h – 24h). During the first part of this period, 
the tail bud becomes visible at the caudal extremity of anterior-
posterior axis. The somitogenesis begins; three somites develop per 
hour. The neural plate becomes thicker and the neural tube forms 
with secondary neurulation. At the end of this period, the yolk is 
divided into a spherical anterior portion (yolk ball) and a cylindric 
posterior portion (yolk extension). At the end of somitogenesis, the 
embryo counts 31 somites (Figure 6.v-z). 
6. Pharyngula period (24h – 48h). In this period, the pharyngeal arches 
primordia become visible. The bilateral symmetry of the embryo 
becomes evident, as the long caudal fin. The brain is divided into five 
lobes and the melanophores, derived from the neural crests, start to 
differentiate: pigmentation of the eye starts at 26h. The head-trunk 
angle is 90° at the beginning of this period, but later this angle 
increases as a consequence of straightening of the embryo. The heart 
beating and circulation can be clearly distinguished; at the end of this 
period the heart is completely formed and the primordia of all the 
organs are present (Figure 7.a-b).  
7. Hatching period (48h – 72h). Zebrafish embryos hatch 
asynchronically, between 48h and 72h. The pectoral fins and the jaws 
become visible. The cranial cartilages form, as the branchial arches; at 
end of this period, the swim bladder starts to be visible. After 72h 
embryos are defined as larvae and can autonomously swim. After 
120h, the yolk is consumed and zebrafish larvae can eat 
autonomously (Figure 7.b-c).  
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Figure 6. Stages of early embryonic development in zebrafish. Zebrafish 
development can be divided into seven periods. This is a schematic 
representation of the changes occurring throughout the first five periods, from 
zygote to segmentation stages (Web and Miller, 2007).  
Figure 7. Stages of late 
embryonic development in 
zebrafish. This is a schematic 
representation of the changes 
occurring throughout the last 
three periods, from pharyngula 
to hatching stages (Kimmel et al., 
1995).  
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p66Shc and p53/p44 in zebrafish 
The only data present in literature suggest a role of Shc proteins in 
postnatal angiogenesis: it has been shown that specific knockdown of 
p52Shc/p46Shc in zebrafish embryos leads to defects of intersegmental vessel 
sprouting angiogenesis (Sweet et al., 2012). The aging-associated isoform of 
Shc, p66Shc, has never been investigated in fish. Nevertheless, through 
bioinformatic analysis it has emerged that the shc locus in zebrafish shows 
conservation with mammals: in Ensemble genome browser is present a 
protein coding putative transcript for p66Shc (ENSDART00000098400). 
Ensemble prediction was used as a reference in this work for molecular 
cloning of the p66Shc full-length cDNA. 
On the contrary, p53 has been extensively investigated in zebrafish. In 
this fish, as in mammals, p53 controls cell cycle in response to different 
stresses: (i) the zebrafish p53 protein shows 48% similarity with human p53 
and, as in mammals, it is expressed during embryogenesis (Cheng et al., 
1997); (ii) p53 knockdown does not affect embryonic development, but it 
impairs DNA damage response upon UV radiation (Langheinrich et al., 2002; 
(iii) p53 accumulates in zebrafish embryos upon treatments with ionizing 
radiations and a known p53-activating agent, the chemotherapeutic drug R-
roscovitine (Lee et al., 2008); (iv) a zebrafish p53 mutant line (named 
p53M214K), that harbours a missense mutation found in human cancer, does 
not show p53-dependent response to ionizing radiation and mutant 
embryos fails to undergo apoptosis, while mutant adults are prone to 
develop malignant peripheral neural sheath tumours (Berghmans et al., 
2005); (v) double mutants that harbour p53M214K and a constitutive active 
form of B-RAF are prone to develop melanomas (Ceol et al., 2008); (vi) 
Unravelling the p53/p66Shc pathway in vivo  
 
34 
 
double mutants that harbour p53M214K and a constitutive active form of RAS 
are prone to develop embryonic rhabdomyosarcomas (Langenau et al., 
2007).  
The existence of a p44 ortholog in zebrafish has been shown by Davidson 
and colleagues in 2010: in this work, the authors isolated, through 3’-RACE 
PCR, a 1.7kb transcript produced by alternative splicing of the p53 mRNA. 
This 1.7kb transcript shows an in-frame STOP codon that does not allow 
full-length p53 translation. It also shows a downstream ATG that encodes 
an N-terminal p53 isoform that lacks the first TAD, as mammalian p44, 
showing an alternative N-terminal amino-acid sequence with no similarity 
with other zebrafish proteins (Figure 8). 
 
Figure 8. Illustration of the mechanism proposed by Davidson et al. for p44 
production in zebrafish. Full-length p53 (FLp53) ATG is located in exon 2. When 
intron 2 is spliced, FLp53 is produced. On the contrary, when intron 2 is retained, 
the STOP codon located in intron 2 blocks FLp53 production (as suggested by the 
diagonal line, the prematurely truncated polypeptide undergoes degradation). In 
the same intron is located, downstream to the STOP codon, an ATG that is used to 
translate p44 (Δ40p53): the resulting protein shares the same sequence of FLp53, 
with the exception of the first transactivation domain.  
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The microinjection of p44 mRNA in wild-type embryos is associated with 
severe developmental abnormalities, such as hypoplasia of the head, eyes 
and somites, and marked embryonic lethality within the seventh day post 
fertilization. Interestingly, the same phenotype is obtained with the 
microinjection of human p44 ortholog. On the contrary, microinjection of 
p44 mRNA in p53M214K embryos does not lead to any morphological 
abnormalities, suggesting that, as previously shown in mammals, the p44 
isoform acts only in cooperation with FLp53. Moreover, p44 
overexpression is evident after treatment with ionizing radiation: as in 
mammals, in zebrafish this isoform is overexpressed in response to stress. 
As its mammalian ortholog, p44 drives the overexpression of p21 in concert 
with p53; in absence of p53, p44 alone is not able to drive p21 expression. 
Finally, knockdown of p21 in p44-overexpressing embryos leads to a partial 
rescue of embryonic abnormalities (Davidson et al., 2010). In summary, this 
work shows that zebrafish p44 recapitulates mammalian p44 functions: 
nevertheless, further efforts are necessary to investigate the role of p44 in 
development, under normal conditions and upon stress. Finally, it is 
important to notice that zebrafish has the unique opportunity to generate 
a knock-out model of p44. The alternative splicing mechanism through 
which p44 is produced gives the chance to selectively knock-out p44 in this 
organism, without interfering with p53 sequence: indeed, in mice it has 
been observed that a point mutation introduced to mutagenize the p44 
ATG leads to a dramatic reduction of the p53 mRNA level, due to its 
instability (Melis et al., 2011). Considering this, a genetic model of selective 
p44 ablation is not feasible in mice.  
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4.1 The short-living killifish Nothobranchius furzeri 
The animal models for research on aging range from invertebrates to 
mammals, which lifespans range from few weeks to years.  
Historically, the worm Caenorhabditis elegans, with a mean lifespan of 
18-20 days, was the first model to be genetically engineered to discover 
genes that regulate the aging process: as an example, the involvement of 
insulin/IGF-1 signalling pathway in aging was revealed in this organism 
(Tissenbaum et al., 1998). Although C. elegans shows enormous advantages 
in aging research (such as the extremely short lifespan, easy genetic 
manipulation, the feasibility of high-throughput genetic screenings for RNA 
interference, the possibility to test simultaneously a variety of molecules) it 
is an invertebrate organism that cannot completely recapitulate vertebrate 
physiology (Olsen et al. 2006).  
Recently, mice have been extensively used in aging research, considering 
also the increasing interest in neurodegenerative diseases and aging-
dependent cognitive decline; but the expensive costs for their maintenance 
and the median lifespan of 2 years are obvious disadvantages, together 
with the rising ethical pressure on replacing mammals, whenever possible, 
with lower vertebrate or invertebrate model organisms.  
Zebrafish has a median lifespan of 3 years and a maximum lifespan of 5.5 
years (Gerhard et al., 2002), even though these numbers are influenced by 
housing conditions and differences in strains. It has been reported that 
zebrafish recapitulates some of the mammalian aging features: spinal 
curvature, accumulation of oxidative damages to proteins in the muscle, 
accumulation of senescence-associated β-galactosidase. Nevertheless, the 
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study of 2-year-old wild-type fish (that cannot be defined old yet) in 
comparison with very young fish of 4-6 months failed to detect differences 
in some aging-associated phenotypes, such as the decrease in telomerase 
activity, the depletion of the stem cell compartment and the accumulation 
of the aging marker lipofuscin. For this reason, it has been proposed that 
zebrafish represents a model of “very gradual senescence” (Kishi et al., 
2003). This issue, together with the prolonged median lifespan, are the 
main problems that counteract the use of zebrafish in aging research. 
However, it is important to point out that recently a genetic model of 
shortened lifespan and premature aging has been produced: the 
telomerase-deficient (tert-/-) zebrafish (Henriques et al., 2013; Anchelin et 
al., 2013) represents a new tool that will improve the use of this species in 
aging research.  
An overview on Nothobranchius furzeri life cycle and age-related 
phenotypes 
In this work, we chose an emerging model organism: the short-living 
killifish Nothobranchius furzeri, first proposed as a model for aging research 
in 2003 (Valdesalici and Cellerino, 2003). This fish is characterized by an 
extremely short lifespan that ranges, depending on the laboratory strain, 
from a minimum of 3 months to a maximum of 12 months: this is the result 
of the evolutional adaptation of N. furzeri to its habitat.  The habitat of this 
killifish consists of seasonal water bodies in Zimbabwe and Mozambique, 
where a long dry season is followed by a brief rainy season: during the 
latter, ephemeral ponds of water appear on the riverside. In this season, N. 
furzeri embryos hatch, they quickly grow and reach sexual maturity at one 
month of age. Killifish reproduce and die before the ponds dry. Killifish 
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embryos are adapted to survive the dry season: they do not develop in 
water, but in humid or dry mud. Depending on the environmental 
conditions (e.g. hypoxia and low temperature), embryos can also enter 
diapause, a state of arrested development (dormancy) during which oxygen 
consumption is reduced at the minimal level that guarantees survival. With 
the new rainy season, killifish embryos, finally in contact with water, hatch.  
(Levels et al., 1986; Valdesalici and Cellerino, 2003; Kim et al., 2016).  
Thanks to the efforts of Nothobranchius researchers, we have now the 
possibility to use sufficiently standardized protocols for laboratory 
husbandry of this fish. In captivity, the reduced competition and the 
controlled conditions allows N. furzeri to live longer, even though it remains 
an annual fish. It is interesting to point out that, nevertheless, the 
reproductive phase of this killifish is not extended by captivity: it becomes 
fertile at one month of age and sterile when it is 6-month-old. After the 
reproductive phase, this killifish rapidly ages showing several aging-
associated phenotypes in common with mammals. It is important to point 
out that, in captivity, killifish reproduction is continuous and not seasonal, 
even if they have a lower fecundity than zebrafish: N. furzeri females lie a 
maximum of ~30 eggs 2/3 times a week. In laboratory conditions, killifish 
embryos usually skip diapause, but their development still takes a long time 
if compared with zebrafish: they hatch after ~3 weeks post-fertilization. For 
these reasons, including the fact that some fundamental techniques of 
developmental biology such as in situ hybridization and transient 
modulation of gene expression are very far from being set up, N. furzeri is 
not considered, nowadays, an advantageous model for developmental 
biology. Nevertheless, recent efforts were made to describe killifish 
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development, especially in relation with the interesting phenomenon of 
diapause (Dolfi et al., 2014; Cellerino et al., 2015).  
As previously mentioned, different N. furzeri laboratory strains are 
available. The first strain is named MZM 04/10: it is original from Southern 
Mozambique, collected in 2010 and thus inbred for less than ten years. It 
has a median lifespan of 6-9 months and a maximum lifespan of 12 months. 
The second strain is named GRZ: it is original from the Gona Re Zhou 
National Park in Zimbabwe and derived from a naturally inbred population, 
collected in 1969. This strain is characterized by an extremely short lifespan 
of 3-6 months. Interestingly, both MZM and GRZ strains reach sexual 
maturity at ~1 month of age, suggesting that the shorten lifespan observed 
in GRZ depends on accelerated physiological decay and not on accelerated 
development (Terzibasi et al., 2008). This has also been confirmed by 
several works: the GRZ strain ages faster than MZM and aging-associated 
features appear earlier in GRZ than in MZM (Di Cicco et al., 2011; Baumgart 
et al., 2012). The extremely short lifespan observed in the GRZ strain is not 
the result of a single mutation: quantitative trait loci (QTL) analyses 
revealed that this trait has a complex multigenic origin (Kirschner et al., 
2012, Cellerino et al., 2015). 
Several efforts have been done by Nothobranchius researchers to 
demonstrate that this fish recapitulates mammalian aging. From a 
macroscopic point of view, it is extremely easy to recognize aging-related 
phenotypes in old fish. After the reproductive phase, fish begin to appear 
more and more emaciated: males lose their colouration, the spinal 
curvature increases, fins become deteriorated. They also spend less and 
less time exploring the environment: locomotor activity and learning 
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performance tests show that old fish encounter rapidly cognitive decline 
(Genade et al., 2005; Valenzano et al., 2006b). Histopathological analyses 
show that, at the basis of this progressive systemic decline, there are aging-
related lesions in multiple organs: kidneys are subjected to nephrocalcinosis 
and, thus, reduced functionality, heart undergoes hypertrophy and liver 
undergoes steatosis: these lesions are common in old vertebrates, including 
humans (Di Cicco et al., 2011; Cellerino et al., 2015). An important aspect in 
Nothobranchius aging is the age-related onset of spontaneous tumours, 
that are rare in other teleost fish: in ~50% of old killifish were found 
neoplastic lesions primarily in the liver (hepatomas and cellular 
hepatocarcinomas) and kidney (Di Cicco et al., 2011).  
Nothobranchius has been shown to accumulate with age several well-
known cellular and molecular aging biomarkers. Lipofuscin is an 
autofluorescent pigment detected in lysosomes of old invertebrates and 
vertebrates, including humans, as a consequence of lipid peroxidation: this 
pigment accumulates in the liver and brain of N. furzeri (Terzibasi et al., 
2008 and 2009). β-galactosidase activity increases with age in mammals, as 
a result of the accumulation of cells that have lost their replicative 
potential: senesce-associated β-galactosidase staining strikingly increases 
with age also in the skin of N. furzeri (Genade et al., 2005), whereas killifish 
liver shows an increasing number of apoptotic cells (Di Cicco et al., 2011). 
Nothobranchius brain shows age-dependent neurodegeneration: a well-
known marker of degenerating neurons, Fluoro-Jade B, accumulates in the 
brain of aging fish (Valenzano et al., 2006b); as in mammals, adult 
neurogenesis is impaired in the old killifish, due to an evident decrease in 
stem cell activity (Terzibasi Tozzini et al., 2012); finally, gliosis (hypertrophy 
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of several types of glial cells) dramatically increases in old fish as in humans 
(Terzibasi Tozzini et al., 2012). Moreover, N. furzeri telomere length is 
similar to humans and telomeres shorten with age in this fish (Hartmann et 
al., 2009). Another molecular biomarker of aging is the reduction of 
mitochondrial DNA (mtDNA) copy number, due to the age-dependent 
increase of mtDNA instability: mtDNA copy number decreases with age in 
Nothobranchius tissues (Hartmann et al., 2011). Finally, genome-wide 
analysis of microRNA expression reveals that they are regulated during 
aging in the N. furzeri brain: in particular, miRNAs that enhance the proto-
oncogene myc activity are downregulated with age, whereas miRNAs that 
enhance the tumour suppressor p53 activity are upregulated. This age-
dependent regulation of miRNA expression is conserved between 
Nothobranchius and primates (Baumgart et al., 2012). Whole-genome 
transcript regulation has also been investigated in the aging brain of N. 
furzeri, revealing strong conservation with humans in terms of 
downregulated and upregulated genes; this analysis also reveals 
uncharacterized genes that are potentially new genetic determinants of 
aging (Baumgart et al., 2014).  
An overview on the available technologies 
Thanks to its short lifespan, N. furzeri represents a valid model for 
longitudinal studies, in which the same animals are monitored from birth to 
death. For this reason, several non-genetic interventions have been applied 
to modulate Nothobranchius lifespan: (i) lowering water temperature 
results in prolonging lifespan and decelerating the onset of aging 
biomarkers (Valenzano et al., 2006a); (ii) resveratrol administration with 
standard diet extends N. furzeri lifespan by the 30% and delays 
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neurodegeneration (Valenzano et al., 2006b); (iii) dietary restriction 
extends median lifespan and slows down aging of the GRZ strain, whereas it 
increases only maximum lifespan of the MZM strain (Terzibasi et al., 2009); 
(iv) treating N. furzeri with very low doses of rotenone, which interferes 
with the mitochondrial ETC, results in 15% lifespan prolongation (Baumgart 
et al., 2016). These studies prove that N. furzeri is a useful model for the 
investigation of the effects of diets and drugs on lifespan and aging. 
Nevertheless, a valid experimental model has to provide the opportunity to 
apply genetic interventions.  
Recently, two fundamental bioinformatic tools were provided to 
Nothobranchius researchers: sequenced, assembled and annotated genome 
(Reichwald et al., 2015; Valenzano et al., 2015) and transcriptome for 
several tissues (Petzold et al., 2013; Valenzano et al., 2015). Moreover, a 
protocol for microinjection in Nothobranchius eggs has been set up 
(Hartmann and Englert, 2012) and transgenesis has been successfully 
applied in this fish using the Tol2 transposon system. Transgenic lines, that 
express the green fluorescent protein (GFP) under different promoters, 
have been generated, proving that N. furzeri can grow up as a model for 
genetic screenings (Valenzano et al., 2011; Allard et al., 2013). Most 
importantly, the CRISPR/Cas9 technique has been used in this model to 
generate several knock-out lines of aging genes involved in nutrient sensing, 
genomic stability, mitochondrial functions, cell senescence and 
proteostasis. The phenotype of a knock-out line deficient for the telomere 
reverse transcriptase (TERT) enzyme has been investigated: as previously 
mentioned, N. furzeri’s telomeres are similar in length to humans’; tert-/- 
killifish undergo age-dependent telomere shortening and develop atrophied 
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gonads and impaired self-renewal of stem cells, showing severe 
dysfunctions in actively proliferating tissues such as testes, blood and 
intestine. The use of CRISPR/Cas9 combined with homology directed repair 
allowed the generation of a knock-out/knock-in killifish line harbouring a 
mutation in the tert gene that corresponds to the mutation found in human 
dyskeratosis congenita (Harel et al., 2015; Kim et al., 2016).  
In conclusion, initial research on N. furzeri provided evidence that this 
fish represents a model of accelerated senescence that recapitulates in less 
than one year all the hallmarks of mammalian aging that have been 
searched so far. Recently, several fundamental tools and techniques have 
been set up in this fish, so that N. furzeri is ready to become the most 
appealing model to investigate genetics of aging.  
p66Shc and p53/p44 in Nothobranchius furzeri 
All the knowledge about the conservation of p66Shc, p53 and its short 
isoform p44, including molecular cloning and sequence analysis, has been 
generated with this work. cDNA sequences of p66Shc and p53 have been 
retrieved using the N. furzeri transcriptome browser (Petzold et al., 2013), 
searching for contigs showing similarity with zebrafish and mammalian 
orthologs. Genomic sequences of p66Shc and p53 were a courtesy of Dr A. 
Cellerino, since when this work began the Nothobranchius genome was not 
published yet.  
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Aim of the project 
Oxidative stress (OS) induced by reactive oxygen species (ROS) increases 
during lifespan and it is involved in the aging process (Campisi, 2005). ROS 
are also important for normal development, since the balance of oxidative 
and reductive forces contributes to fine tune the balance of proliferation 
and differentiation (Dennery, 2007). On these bases, key regulators of 
intracellular ROS levels have a role in both aging and development: two 
well-known players in OS response are p66Shc and p53. p66Shc is activated 
upon OS and it is responsible for p53-dependent apoptosis. p66Shc-/- mice 
are resistant to OS-induced apoptosis (Migliaccio et al., 1999) and they are 
considered a model of healthy aging (Zaccagnini et al., 2004; Menini et al., 
Koch et al., 2008). The role of p66Shc in development has not been 
investigated, but some evidence suggests that it can have a function in 
neuronal differentiation (Conti et al., 1997; Papadimou et al., 2009). p53 is 
universally known for its role in tumor suppression, but little is known on its 
role in aging: it has emerged that the p44 isoform of p53, which is also 
present in zebrafish (Davidson et al., 2010), could be the key regulator of 
p53 role in stress response (Bourougaa et al., 2010) and aging (Maier et al., 
2004). Intriguingly, the p44 isoform appears to have an opposite role on 
p53 during development, when it is involved in cell proliferation, blocking 
p53-dependent differentiation (Ungewitter and Scrable, 2010). Recently, it 
has been demonstrated that p44/p53 and p66Shc participate altogether in a 
transcriptional regulation network that triggers, specifically upon OS, in 
vitro cell cycle arrest, through downregulation of G2/M genes (Gambino et 
al., 2013). Taking advantage of two animal models, the teleost fish Danio 
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rerio and Nothobranchius furzeri, this work has been tailored to address 
two main objectives:  
1. Evaluating whether, in our models, p53/p44 and p66Shc are present 
and conserved, through molecular cloning of the ortholog genes, 
sequence analyses, characterization of their expression patterns and 
functional analyses. 
2. Using the CrispR-Cas9 technique to produce a genetic model of p44 
ablation in zebrafish, in order to elucidate the role of this isoform in 
the orchestration of p53-dependent stress response in development. 
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Main results 
The first part of my project has been focused on the identification 
through molecular cloning and sequence analyses of the Danio rerio 
ortholog of p66Shc and the Nothobranchius furzeri orthologs of p53, p44 and 
p66Shc. These results are collected in the paper published on Aging and 
Disease, included in Part II of the present thesis. Here below the main 
findings obtained: 
1. A p66Shc isoform of the shc1 gene is expressed in D. rerio and N. 
furzeri. 
2. Sequence analyses of p66Shc and p53 orthologs of D. rerio and N. 
furzeri show that the key aminoacidic residues and domains are 
conserved between these fish and mammals. This fact suggests that 
fish proteins can recapitulate mammalian ortholog functions. 
The second part of my project was focused on the initial characterization 
of the role of (i) p66Shc in zebrafish development and (ii) N. furzeri p53/p44 
in stress response. The results obtained are not organized in a manuscript 
and they are included in Part III of this thesis. Here below the main findings 
obtained: 
1. p66Shc expression is restricted to the cephalic area in zebrafish 
development: 
a. At 24hpf, p66Shc expression is ubiquitous, but concentrated in 
the head, in the trigeminal placodes and in Rohon-Beard 
neurons, transient mechanoreceptors located dorsally in the 
Unravelling the p53/p66Shc pathway in vivo  
 
47 
 
spinal cord, that undergo programmed cell death after 24hpf 
(Reyes et al., 2004).  
b. At 48hpf, p66Shc expression is localized (i) in the brain and in 
particular in the optic tectum, (ii) in the ciliary marginal zone of 
the retina, where retinal stem cells and retinal progenitor cells 
are located (Moshiri et al., 2004), and (iii) in the trigeminal 
ganglion, where the nuclei of the touch-sensory neurons of the 
fifth cranial nerve are located (Kimmel et al., 1995).  
c. At 72hpf and 96hpf, p66Shc expression is still restricted to the 
cephalic area and it is concentrated in the optic tectum, in the 
ciliary marginal zone of the retina and in the trigeminal 
ganglion. 
2. p66Shc was successfully discriminated from p52Shc: at 24hpf and 48hpf, 
p52Shc expression is not spatially restricted, being ubiquitously 
distributed in the embryo. 
3. p66Shc mRNA levels increases at later developmental stages: mRNA 
levels of p66Shc are very low at early developmental stages and 
dramatically increases reaching a peak at 48hpf-72hpf. On the 
contrary, mRNA levels of p52Shc are stable over time. 
4. p44 and p53 share the same expression pattern: at 48hpf, p53 and 
p44 are both expressed (i) in the midbrain-hindbrain boundary; (ii) in 
the retina; (iii) in the fin buds; (iv) in the pharyngeal arches; (v) in the 
otic vesicles and (vi) in the hatching glands. 
5. Nothobranchius p66Shc is expressed in adult tissues: we cloned the N. 
furzeri ortholog of p66Shc and proved that it is expressed in several 
adult tissues (brain, heart, liver, intestine and muscle). 
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6. Nothobranchius p53 (Np53) and p44 (Np44) partially recapitulate 
mammalian p53/p44 functions in oxidative stress response:  
a. We identified the putative Np44 by sequence analysis of p53 
genomic sequence; the full-length cDNA sequence of Np44 has 
been cloned and found expressed in several adult tissues (brain, 
heart, intestine and testes). 
b. In p53-/- MEFs reconstituted with either Np53 or Np44 and 
treated with H2O2 or doxorubicin, cell senescence is induced by 
Np53 also at basal conditions, whereas it is induced by Np44 
only upon treatments. 
c. In p53-/- MEFs reconstituted with either Np53 or Np44 and 
treated with H2O2 or doxorubicin: (i) G2/M genes are not 
downregulated by Np53 upon treatments; (ii) G2/M genes are 
downregulated by Np44 upon treatment with H2O2 but not 
doxorubicin; (iii) p21 upregulation is induced by Np53 upon 
both the treatments; (iv) p21 upregulation is mildly induced by 
Np44 only upon doxorubicin treatment. 
The third part of this work has been focused on the generation and initial 
characterization of the p44-/- model in D. rerio (zebrafish). These results are 
collected in a manuscript in preparation; this will be concluded with the 
results of functional experiments planned to unravel the role of p44 in 
stress response during development. Here below the main findings already 
obtained: 
1. Three different p44-/- lines have been generated in zebrafish taking 
advantage of the CRISPR/Cas9 technique. In these three lines, the 
correct splicing of full-length p53 is unaltered. 
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2. In the p44-/- line used for further investigations, mRNA levels of full-
length p53 are comparable to those of wild-type (WT; data obtained 
with Real-Time RT-PCR).  
3. Preliminary data obtained by semiquantitative RT-PCR data show 
that: 
a. p44 and Δ113p53 mRNA levels are comparable between p44-
/- and WT.  
b. Δ113p53 expression is low at mid-blastula transition, then it 
reaches a peak at gastrulation and it slightly decreases until 
120hpf. 
4. A preliminary experiment in which p44-/- and WT embryos were 
treated with the p53-activating agent R-roscovitine (Lu et al., 2001; 
Guo et al., 2010) shows that: (i) phenotypic differences are not 
detectable between p44-/- and WT embryos upon treatment; (ii) p44 
expression is induced in a dose-dependent manner, in particular in 
WT embryos; (iii) p21 expression is poorly induced upon treatment 
with both doses; (iv) p53 expression is stable; (v) Δ113p53 
dramatically increases in p44-/- and WT embryos in a dose-dependent 
manner; (vi) p66Shc expression is stable in WT embryos upon 
treatment, while it results strongly induced in the p44-/-. 
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Conclusions and future perspectives 
The role of p66Shc in aging has been extensively investigated, but the 
mechanisms involved are still to be elucidated. Our aim is to investigate 
p66Shc genetics taking advantage of the short-living vertebrate 
Nothobranchius furzeri. This teleost fish is an emerging model in which the 
generation of transgenic (Valenzano et al., 2011; Allard et al., 2013) and 
CRISPR/Cas9-mediated knock-out lines (Harel et al., 2015) are feasible, as 
well as screenings of compounds affecting lifespan and healthspan 
(Valenzano et al., 2006b). We used the N. furzeri transcriptome browser 
(Petzold et al., 2013) to identify the ortholog of p66Shc (Np66Shc) and proved 
that it is expressed in several adult tissues. Our sequence analyses show 
that the aminoacidic domains important for p66Shc to exert its functions are 
conserved in N. furzeri. This is the basis for further functional analyses: 
heterologous complementation experiments in p66Shc-/- mammalian cells 
will be useful to elucidate whether Np66Shc is able to initiate OS response, 
as in mammals. Further investigations include in vivo analyses of Np66Shc 
expression changes under different environmental conditions or stresses 
and the generation of a genetic model of Np66Shc overexpression or 
ablation.  
Since p66Shc-/- mice are viable and p66Shc-/- embryos are not 
counterselected during gestation, few attentions have been focused on 
understanding whether p66Shc may have a function in development. The 
recent debate on differences in phenotypic effects obtained with gene 
knockdown and mutagenesis highlighted that mechanisms of genetic 
compensation may explain why deleterious mutations have sometimes no 
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morphological effects, while gene knockdown leads to abnormal 
development: mutations in the genome can trigger up- or downregulation 
of genes related to the ablated one (Rossi et al., 2015). This means that the 
ablated gene has not to be considered “necessary”, but, nevertheless, it is 
“functional”. In fact, although p66Shc is not necessary to complete 
embryogenesis, there are some evidence suggesting a function in neuronal 
differentiation (Conti et al., 1997; Papadimou et al., 2009). Through 
bioinformatic analysis it has emerged that the shc locus in zebrafish shows 
conservation with mammals. Ensemble prediction was used as a reference 
for molecular cloning of the p66Shc full-length cDNA, demonstrating for the 
first time that this isoform is expressed in zebrafish and that the functional 
domains present in the N-terminal sequence unique to p66Shc are 
conserved. Moreover, Real-Time RT-PCR and whole-mount in situ 
hybridization analyses on zebrafish embryos show that the shorter and the 
longest isoforms of shc1 are differently regulated in zebrafish development. 
p52Shc behaves as a housekeeping gene, whereas p66Shc is temporally 
regulated: its mRNA levels reach a peak between 48hpf and 72hpf, during 
the organogenesis process, when areas of active cell proliferation become 
more and more restricted and the vast majority of cell types are 
differentiated (Kimmel et al., 1995). Whole-mount in situ hybridization of 
p66Shc shows that its expression is concentrated, until 24hpf, in neural 
crest-derived structures. After 48hpf, interestingly, p66Shc is expressed only 
in the cephalic area: (i) in the optic tectum, where neural progenitors are 
located (Ito et al., 2010); (ii) in the ciliary marginal zone of the retina, where 
retinal stem cells and retinal progenitor cells are located (Moshiri et al., 
2004) and (iii) in the trigeminal ganglion. Our findings are in agree with 
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literature data and they suggest that p66Shc might be involved in brain 
development and in the specification of neural crest-derived structures, 
where it appears to be strongly expressed. Experiments of double in situ 
hybridization of p66Shc together with neural stem cell markers (e.g. 
musashi-1; Sakakibara et al., 1996) and neural crest markers (e.g. islet-1; 
Inoue et al., 2004) will confirm that p66Shc is localized in these cell types.  
The tumour suppressor p53 is involved, as p66Shc, in stress response, 
lifespan and aging modulation. p44 is a short isoform of p53 that has been 
demonstrated to orchestrate p53 functions in stress response and aging. As 
for p66Shc, our aim is to take advantage of N. furzeri to investigate the 
mechanisms through which p44 acts on p53. We identified the putative p44 
ortholog by sequence analysis of the N. furzeri p53 genomic locus. We 
demonstrated that the full-length cDNA sequence of Np44 is expressed at 
low levels in several N. furzeri adult tissues. Moreover, our preliminary 
results of heterologous complementation experiments in p53-/- MEFs 
reconstituted with either Np53 or Np44 show that: (i) Np53 induces cell 
senescence upon OS and genotoxic stress (GS), but also at basal conditions; 
(ii) Np53 is not able to downregulate the 31 G2/M genes but it induces the 
upregulation of p21; (iii) Np44 is able to induce the downregulation of 
G2/M genes only upon OS. Future experiments have to be planned in order 
to modulate Np53 expression in p53-/- MEFs: in fact, Np53 is able to induce 
cell cycle arrest also at basal conditions. This makes the other results 
difficult to interpret. In mammals, p44 is implicated in OS response 
(Gambino et al., 2013). This fact suggests that Np44 might recapitulate 
mammalian p44 functions in orchestrating the p53-dependent 
transcriptional response to different kinds of stress agents. In vivo 
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experiments in N. furzeri will clarify whether Np44 is indeed activated by OS 
and in which tissues is preferentially expressed upon OS and at basal 
conditions. Moreover, being N. furzeri the shortest-living vertebrate model 
organism, a p44-/- model in this fish will be also fundamental to deeply 
investigate the role of p44 in aging and lifespan modulation.  
In this study, we analysed p53 and p44 expression patterns during 
zebrafish development through in situ hybridization. In mammals, the main 
function of p44 during early embryogenesis is to suppress p53 activity to 
preserve pluripotency (Ungewitter and Scrable, 2010). p44 and p53 share 
the same expression patterns in 48hpf embryos. Both the isoforms are 
expressed in areas of persistent cell proliferation, such as the midbrain-
hindbrain boundary (Wulliman and Knipp, 2000) and the fin buds (Nomura 
et al., 2006). It is not surprising that p53 and p44 are expressed in the same 
areas, considering that (i) p44 has been described as a splicing isoform of 
p53 (Davidson et al., 2010) and (ii) it is demonstrated that p44 has to 
interact with p53 to exert its functions (Maier et al., 2004; Ungewitter and 
Scrable, 2010). Interestingly, both p53 and p44 are expressed in areas of 
extensive cell proliferation: this observation is consistent with previous data 
showing that p44 and p53 cooperate during embryogenesis in maintaining 
the balance between proliferation and differentiation (Ungewitter and 
Scrable, 2010).  
Importantly, the alternative splicing mechanism through which p44 is 
produced in zebrafish gives the chance to selectively knock-out p44, 
without interfering with p53 sequence. In mice, it has been observed that a 
point mutation introduced within the p44 ATG leads to a dramatic 
reduction of the p53 mRNA level due to its instability (Melis et al., 2011). 
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Considering this, a genetic model of selective p44 ablation is not feasible in 
mice. Taking advantage of the CRISPR/Cas9 technology, we generated three 
different stable lines of p44-/- zebrafish in which the full-length p53 mRNA is 
unaltered. Real-Time RT-PCR of p53 at different developmental stages 
shows that p53 mRNA levels are comparable between p44-/- and wild-type 
(WT) embryos at each developmental stage. This data demonstrates that in 
our model only p44 is depleted.  
Preliminary data obtained by semiquantitative RT-PCR show that mRNA 
levels of p44 and the shortest isoform of p53, Δ113p53, are comparable 
between p44-/- and WT embryos and that the two isoforms are differently 
regulated. Preliminary data obtained by treating p44-/- and WT embryos at 
gastrulation stage with the p53-activating agent R-roscovitine (Lu et al., 
2001; Guo et al., 2010) suggests that p44 expression is dramatically induced 
by this drug. Moreover, the absence of phenotypic differences between 
p44-/- and WT upon treatment might be the result of a genetic 
compensation mechanism. In particular, p66Shc expression is induced in a 
dose-dependent manner in treated p44-/- embryos. Further experiments are 
needed to confirm our hypothesis. Other p53-activating agents will be 
tested in order to evaluate how p44 orchestrates stress response in 
development. In particular, we will induce OS and GS response in zebrafish 
embryos to validate in vivo the hypothesis that p44 is in particular involved 
in transcriptional regulation in response to protein damage (Bourougaa et 
al., 2010; Gambino et al.; 2013).   
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Summary 
Δ40p53 is a short isoform of p53 lacking the first TAD and MDM2 
binding domain. Δ40p53 is involved in stress response, in particular upon 
protein damage, and it forms tetramers with p53, orchestrating its 
transcriptional activity. Zebrafish gives the unique opportunity to generate a 
knock-out model of Δ40p53, since the targeted mutation of Δ40p53 ATG in 
mice impairs the stability of p53 transcript, leading to p53 partial loss of 
function. We report here the CRISPR/Cas9-mediated generation of three 
Δ40p53-/- stable lines. Δ40p53-/- embryos are not counterselected and do not 
show developmental abnormalities. We demonstrate that, in our model, the 
integrity of full-length p53 mRNA is maintained, as p53 mRNA levels 
throughout development. So far, this is the first attempt of knocking-out a 
specific isoform of a gene: with our findings, we propose the use of 
CRISPR/Cas9 technology to efficiently editing splicing isoforms without 
altering the expression of the other mRNAs transcribed from the same locus. 
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Our Δ40p53-/- model represents a valuable tool to dissect in vivo p53 
transcriptional activity in response to different stress agents and 
physiological development. 
Introduction 
Genome editing via the Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR)/Cas9 technology has given a new boost to 
zebrafish (Danio rerio) as a model to investigate vertebrate physiology and 
human pathologies. So far, targeted mutagenesis in zebrafish was only 
possible using Zinc-Finger Nucleases (ZFNs) or Transcription Activator-
Like Effector Nucleases (TALENs). These two systems have several 
disadvantages (high costs, design limitations, procedure difficulties), so that 
site-directed genome editing in zebrafish has remained prohibitive for many 
laboratories (Hruscha et al., 2013). By contrast, the CRISPR/Cas9 system 
turned out to be extremely versatile, inexpensive and fast. Since its first 
applications in 2013 (Hwang et al., 2013a; Chang et al., 2013), several 
improvements to CRISPR/Cas9 technique have been made: (i) the use of 
Cas9 protein (also codon-optimized for zebrafish), instead of Cas9 mRNA, 
increases its mutagenic activity (Jao et al., 2013; Gagnon et al., 2014); (ii) 
co-injection of a donor plasmid with the short guide RNA (sgRNA) and the 
Cas9 mRNA results in site-directed knock-in of DNA cassettes into the 
genome, by homology-independent double-strand break (DSB) repair 
pathways (Auer et al., 2014; Kimura et al., 2014; Hisano et al., 2015); (iii) 
the use of a CRISPR/Cas9 vector system allows tissue-specific gene knock-
out (De Santis et al., 2016). Here, we report the first application of the 
CRISPR/Cas9 technology to specifically knock-out a splicing isoform of a 
gene: the Δ40p53 isoform of p53. We also demonstrate that the small 
INDELs induced by Cas9 cleavage and Non-Homologous End-Joining 
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(NHEJ) repair do not produce aberrant splicing events and do not alter 
mRNA levels of the other p53 isoforms. 
Known for being the “guardian of the genome”, p53 is the most 
frequently mutated protein in human cancer (Vogelstein et al., 2010). p53 is 
active mainly in cell cycle control.  Different levels of stress and damages to 
macromolecules can trigger different p53-dependent transcriptional 
responses that lead to transient cell cycle arrest, apoptosis and cell 
senescence (Bargonetti and Manfredi, 2002). However, it is still unclear how 
a single gene can orchestrate such a wide range of different pathways in 
response to a plethora of signals. This complexity can be explained by the 
finding that the p53 gene encodes several p53 isoforms through the use of 
internal promoters, internal ribosomal entry site (IRES) and alternative 
splicing. These mechanisms are responsible for the production of the 12 p53 
isoforms already identified in humans, that are distinguishable for the 
presence of different domains and specifically regulated (Khoury and 
Bourdon, 2011).   
In this study, we focus on a short isoform of p53, named Δ40p53, 
encoded by the p53 gene. In mammals, the canonical p53 transcript encodes 
Δ40p53 thanks to an IRES located in exon 4. This isoform lacks the first 
TAD, but retains the second TAD and all the p53 functional domains, 
maintaining the ability to form oligomers with the canonical p53 protein. 
Together with the first TAD, Δ40p53 lacks the MDM2 binding domain: it 
has been demonstrated that Δ40p53 is unable to complex with MDM2 
avoiding ubiquitination and degradation (Courtois et al., 2002; Yin et al., 
2002; Ungewitter and Scrable, 2010).  
The Δ40p53 isoform determines p53 functions in stress response, aging 
and development. It is known that Δ40p53, thanks to its intact 
oligomerization domain, has the ability to form oligomers with p53, 
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determining its localization (Ghosh et al., 2004) and fine-tuning its 
transcriptional activity: (i) endoplasmic reticulum (ER) stress promotes the 
formation of Δ40p53/p53 oligomers leading to G2 arrest of the cell cycle 
(Bourougaa et al., 2010) (ii) the human Δ40p53 ortholog accumulates in 
response to genotoxic stress enhancing p21 expression (Powell et al., 2008); 
(iii) Δ40p53, in concert with p53 and via the activation of the aging protein 
p66Shc, induces cell cycle arrest at G2/M transition specifically upon 
oxidative stress-induced cellular damage (Gambino et al., 2013). The 
formation of oligomers between Δ40p53 and p53 depends on protein levels 
of these two isoforms. Since Δ40p53 lacks the MDM2 binding domain, 
Δ40p53/p53 heterotetramers are more stable than p53 homotetramers, 
resulting in the modulation of p53 transcriptional activity (Ungewitter and 
Scrable, 2010).  
It has been observed that Δ40p53 might play also a role in physiological 
development: in mESCs derived from wild-type mice, p53 and Δ40p53 
levels are high and decrease together with the loss of pluripotency. High 
levels of Δ40p53 are observed in embryos immediately after implantation. 
Therefore, Δ40p53 has been considered an embryonic isoform of p53 
(Ungewitter and Scrable, 2010). However, the role of Δ40p53 in normal 
somatic tissues is far from being elucidated in vivo.  
So far, only full-length p53 and the short isoform Δ113p53 have been 
extensively investigated in zebrafish (Langheinrich et al., 2002; Berghmans 
et al., 2005; Lee et al., 2008; Guo et al., 2010; Gong et al., 2015). However, 
it has been discovered that a Δ40p53 ortholog is present in zebrafish. 
Davidson and colleagues isolated, through 3’ RACE PCR, a 1.7kb transcript 
produced by alternative splicing of the p53 mRNA. This 1.7kb transcript 
shows an in-frame STOP codon that does not allow full-length p53 
translation. It also shows a downstream ATG that encodes an N-terminal p53 
Unravelling the p53/p66Shc pathway in vivo  
 
89 
 
isoform lacking the first TAD, as mammalian Δ40p53, replaced by an 
alternative N-terminal amino-acid sequence with no similarity with other 
zebrafish proteins. The microinjection of Δ40p53 mRNA in wild-type 
embryos is associated with severe developmental alterations and embryonic 
lethality. Interestingly, the same phenotype is obtained with the 
microinjection of human Δ40p53 ortholog. On the contrary, microinjection 
of Δ40p53 mRNA in p53M214K embryos (harbouring a dominant negative 
mutation of p53; Berghmans et al., 2005) does not lead to any morphological 
alteration, suggesting that, as previously shown in mammals, the Δ40p53 
isoform acts only in cooperation with p53. Moreover, Δ40p53 expression 
increases after treatment with ionizing radiation. As its mammalian ortholog, 
Δ40p53 drives the overexpression of p21 in concert with p53 (Davidson et 
al., 2010). In conclusion, this work shows that zebrafish Δ40p53 
recapitulates mammalian Δ40p53 functions: nevertheless, further efforts are 
necessary to investigate the role of Δ40p53 in development, under normal 
conditions and upon different stresses.  
Remarkably, zebrafish gives the unique opportunity to generate a knock-
out model of Δ40p53. Indeed, Δ40p53-/- mice are not available, because 
murine Δ40p53 is produced by an ATG contained in p53 exon 4. The 
targeted mutation of Δ40p53 ATG impairs the stability of p53 transcript 
(Melis et al., 2011), leading to p53 partial loss of function. Considering this, 
mice do not represent a good model to investigate effects of Δ40p53 
ablation.  
We report here the generation and preliminary characterization of the first 
Δ40p53-/- model, produced in zebrafish, that lacks specifically this isoform. 
Our Δ40p53-/- has the unique advantage of retaining the intact full-length 
p53 mRNA and expression levels.  
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Materials and Methods 
Zebrafish strains and maintenance 
Zebrafish (Danio rerio) from wild-type AB and Δ40p53-/- strains were 
maintained and bred at the Zebrafish facility of the FIRC Institute of 
Molecular Oncology accordingly to the national guidelines (Italian decree “4 
March 2014, n° 26”). All the experimental procedures were approved by the 
internal OPBA (Organismo Preposto al Benessere Animale) and the Italian 
Ministry of Health (Project n° 1021/16). 
 
Target site selection 
Target site was selected within the specific Δ40p53 sequence in p53 
intron 2. The target site matches the sequence 5’G-N18-NGG and has been 
checked for specificity in the zebrafish genome using the online tool 
“Optimized CRSPR Design Target Finder”, developed by Dr Zhang 
laboratory at Massachusetts Institute of Technology (crispr.mit.edu:8079/; 
zebrafish genome reference: danRer7).  
 
sgRNA template generation and transcription 
In order to generate a template for sgRNA transcription, we used the 
DR274 plasmid (Addgene, #42250; Hwang et al., 2013a) and the cloning-
free method already described in Burg et al., 2016. A first PCR was 
performed using M13 forward primer (M13Fw, Burg et al., 2016, 
Supplementary material) and a target-specific reverse primer (“CustomRv”, 
Supplementary material), containing the T7 promoter sequence, the target 
sequence without the PAM where the initial T is substituted with a G to 
achieve the best performance by T7 polymerase, and a 3’ sequence that 
anneals perfectly to DR274 plasmid. A 25 cycle PCR was run as follows: 
15ng of plasmid template, 2U of Phusion High Fidelity DNA Polymerase 
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(NEB), 0.2mM dNTPs and 0.5µM each primer with an annealing 
temperature of 59°C. The 321bp amplicon was then purified with the Gel 
Extraction Kit (QIAGEN), according to the manufacturer instructions. The 
second PCR was performed using T7 forward primer (“T7Fw”, Burg et al., 
2016, Supplementary material) and the sgRNA reverse primer (“sgRNARv”, 
Burg et al., 2016, Supplementary material); a 25 cycle PCR was run using 
45ng of the previews amplicon as a template and an annealing temperature 
of 53°C. The 120bp amplicon was purified by QIAquick PCR Purification 
Kit (QIAGEN). The sgRNA was transcribed (2h at 37°C) using the 
MEGAshortScript (Ambion) according to the manufacturer instructions. The 
sgRNA was then DNAse treated (15’ at 37°C with TURBO DNAse, 
Ambion) and precipitated with ammonium acetate/ethanol, according to the 
procedure described in Hruscha and Schmidt, 2014.  
 
Cas9 protein expression and purification 
The Cas9 protein was produced and purified by G. Ossolengo 
(Pepservice, Cogentech SCARL). Cas9 was expressed in bacteria as Cas9-
MBP-His6 fusion protein using the pMJ806 plasmid (Addgene, #39312; 
Jinek et al., 2012) and purified by Immobilized Metal Affinity 
Chromatography (IMAC). The Cas9 was then separated from its fusion 
partners MBP-His6 by cleavage with the TEV enzyme followed by IMAC 
and re-purified with Ion Exchange Chromatography.   
 
Microinjection and initial screening 
Zebrafish zygotes were collected and microinjected through the chorion 
under an Olympus SZX9 using the Picospritzer III microinjector (Parker 
Instrumentation); microinjection needles were prepared pulling GC100F-10 
glass capillaries (Harvard Apparatus) with a P-97 puller (Sutter Instrument). 
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Each zygote was microinjected directly into the single cell with 2nl of the 
following microinjection mix, that has been previously incubated 5 minutes 
at room temperature: 1mg/ml Cas9 protein, 50ng/µl sgRNA, 300mM NaCl, 
1mg/ml dextran rhodamine (Sigma-Aldrich) in RNAse free water; thus, each 
embryo received 2ng of Cas9 protein and 100pg of sgRNA. In total, 300 
embryos born from 5 AB couples were microinjected; 100 embryos were not 
microinjected and used as negative controls to evaluate lethality at 24hpf. 
72hpf embryos were collected for single embryo gDNA extraction. 
 
gDNA extraction and T7 assay 
Single embryos or pools of 10 embryos were lysed over night at 55°C in 
lysis buffer (10mM Tris HCL pH=8, 1mM EDTA, 0.3% Tween-20, 0.3% 
NP-40) + 1mg/ml Proteinase K. gDNA was purified by phenol/chloroform 
extraction and precipitated with ammonium acetate/ethanol. 100ng of gDNA 
were then used as template to amplify the genomic region surrounding the 
Δ40p53 target site with specific primers (“Δ40g”, Supplementary material). 
A touchdown PCR was run from an annealing temperature of 63°C to 57°C 
for 35 cycles. Then the PCR products was denatured/renatured to allow the 
formation of heteroduplex (mutated/wild-type PCR products) as follows: 
95°C 10’, -2°C/s to 85°C, -0.3°C/s to 25°C. After denaturation/renaturation, 
500ng of the PCR product was digested with 2.5U of T7 endonuclease I 
(NEB) for 25’ at 37°C. The formation of the heteroduplexes cleaved by T7 
endonuclease was then assessed by electrophoresis on 2% agarose gel.  
 
Genotyping of heterozygous fish  
Adult fish born from the mating of wild-type and chimeric fish were 
genotyped by gDNA extraction from a 2mm portion of the caudal fin. gDNA 
extraction was performed as previously described. Amplification of the 
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genomic region surrounding the Cas9 target site and subsequent T7 assay 
was performed as previously described. PCR amplicons from fish resulted 
positive to T7 assay were cloned into the pCR 2.1-TOPO vector (Invitrogen) 
following the manufacturer instructions. Six clones for each fish were then 
sequenced and electropherograms analysed with Chromas lite software 
(Technelysium) to identify INDEL mutations. For the chosen Δ40p53-/- line, 
an assay was designed to genotype fish by a single PCR, where the two 
forward primers anneal specifically to the wild-type or the mutated allele 
(“wt” and “mut”, Supplementary material).  
 
Evaluation of full-length p53 expression  
Three pools of 20 48hpf Δ40p53-/- embryos and two pools of respective 
siblings for each line were used for total RNA extraction with Qiazol 
Reagent (QIAGEN) according to the manufacturer instructions. After 
extraction, 30µg of total RNA were treated with 6U of TURBO DNase 
(Ambion) for 30’ at 37°C and then column purified (Quick-RNA MiniPrep 
kit, Zymo Research). 1µg of total RNA was then retrotranscribed 1h at 42°C 
for cDNA synthesis using 0.5µg of a primer mix consisting in oligodT and 
random primers (Invitrogen) in 3:1 ratio, 160U of ImProm-II Reverse 
Transcriptase (Promega), 3mM MgCl2, 0.3mM dNTPs and 20U of RNAse 
Inhibitor (NEB).  Full-length p53 mRNA levels and presence of aberrant p53 
transcripts were then investigated by RT-PCR using specific primer for full-
length p53 (“FLp53”, Table1) and β-actin (“βact”, Table1), used as 
housekeeping gene. A 30-cycle touchdown PCR (annealing temperature 
decreasing from 63°C to 54°C) was run as follows: ~200ng of cDNA as 
template, 0.2µM each primer, 1.5mM MgCl2, 0.3mM dNTPs and 2.5U of 
Taq polymerase (Qiagen).  
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Evaluation of p53, Δ40p53 and Δ113p53 expression during development 
Three pools of 30-50 Δ40p53-/- and Δ40p53+/+ embryos for each 
developmental stage were used for total RNA extraction as previously 
described. cDNA was then synthetized using 0.5µg of oligodT primers only. 
To investigate p53 expression, a two-step qPCR was run using ~100ng of 
cDNA as template, 0.2µM each primer and Fast SYBR Green Master Mix 
2X (Applied Biosystems) in a total volume of 20µl. qPCR was run as 
follows: 2’ at 95°C, then 3’’ at 95°C and 30’’ at 60°C for 40 cycles. p53 was 
discriminated from other isoforms using specific couples of primers (“qp53”, 
Supplementary material); eEF1α-1a was used as housekeeping gene (HK). 
Results are presented as the ratio between as the ratio between AvgCtHK and 
AvgCtp53.  
In order to investigate Δ40p53 and Δ113p53 expression during 
development, we considered one pool of Δ40p53-/- and Δ40p53+/+ siblings 
for each developmental stage. We performed a preliminary semiquantitative 
RT-PCR using ~100ng of cDNA as template, 0.2 µM each primer, 0.3mM 
dNTPs, 1.5mM MgCl2, 0.5U Taq Polymerase (Qiagen). RT-PCR was run as 
follows: 3’ at 94°C, 1’ at 94°C, 1’ at 60°C, 30’’ at 72°C for 30 cycles, 10’ at 
72°C. 5ul of each PCR reaction was run on 2% agarose gel. eEF1α-1a was 
used as HK. Primers for Δ40p53 and Δ113p53 are specific for each isoform 
(“qΔ40” and “qΔ113”, Supplementary material).  
 
Evaluation of transcriptional response to R-roscovitine treatment 
As a pilot experiment, 50 Δ40p53-/- and Δ40p53+/+ siblings at gastrulation 
stage (6hpf) were treated with R-roscovitine (Calbiochem). R-roscovitine 
was dissolved in DMSO and then diluted in E3 water to a final concentration 
of 50µM or 100µM. The final concentration of DMSO was 0.1%; 0.1% 
DMSO in E3 water was used as control treatment. Before treatment, 
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embryos were dechorionated 5’ at 37°C with 2mg/ml Pronase (Sigma-
Aldrich) in E3 water and then rinsed in E3 water. R-roscovitine treatment 
lasted 16h. Embryos were collected at 24hpf and immediately frozen. RNA 
extraction and cDNA synthesis were performed as previously described. 
qPCR for p53, Δ40p53, Δ113p53, p21 and p66Shc was run as previously 
described. In this case, we used top1 as housekeeping gene. Primers for each 
gene are listed in the Supplementary material. The 2(-∆∆CT) method was used 
for relative quantification of gene expression; values relative to untreated 
Δ40p53+/+ siblings were used as calibrators.  
 
Results 
Δ40p53, an N-terminally truncated isoform of p53, is produced in 
zebrafish by an alternative splicing mechanism. The full-length p53 ATG is 
located in exon 2: when the downstream intron is partially retained (as 
described in Davidson et al., 2010), an in-frame STOP codon leads to 
premature end of p53 translation. The downstream Δ40p53 ATG, contained 
in the retained intron, is used for Δ40p53 translation: as a result, this isoform 
shows a unique N-terminal domain, but it lacks the first p53 transactivation 
domain (TAD) and shares all the other functional domains with p53 (Figure 
1.A).  
 
Selective ablation of the Δ40p53 isoform in zebrafish  
In order to selectively knock-out this isoform without altering full-length 
p53 coding sequence (CDS), we looked for a Cas9 target site within the 
specific Δ40p53 CDS located in p53 intron 2. We found a Cas9 target site 
that matches the sequence 5’TG-N18-NGG; this has been checked for 
specificity in the zebrafish genome (danRer7) using the online tool 
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“Optimized CRSPR Design Target Finder” (crispr.mit.edu:8079/; Dr Zhang 
lab - MIT). This target sequence is extremely close to Δ40p53 ATG (Figure 
1.A). Since it has been shown that 5’GG- and 5’AG- are preferentially 
accepted as initiating bases for T7 RNA polymerase (Hwang et al., 2013a), 
we replaced the 5’T- with a 5’G- to generate the template for in vitro 
transcription of the sgRNA. This substitution is not expected to reduce 
efficiency or specificity of the Cas9 cleavage since the mismatch in position 
1 of the target sequence is well tolerated by Cas9 (Anderson et al., 2015). 
We generated the sgRNA through a cloning-independent method that 
requires a custom oligonucleotide (containing the target sequence without 
the PAM) and the DR274 plasmid (Hwang et al., 2013a) as a template. 
Nested PCR was used to generate the template for in vitro transcription of 
the sgRNA. 
A representation of the pipeline used to generate the three Δ40p53-/- lines 
is represented in Figure 1.B. Briefly, we performed an initial screening on 
microinjected embryos to confirm that we successfully induced mutations 
within the Δ40p53 unique sequence (Figure 1.B.b). Then, we raised mosaic 
fish to sexual maturity and crossed them with wild-type animals (Figure 
1.B.c). Following this, we screened the offspring to identify “carrier” mosaic 
fish, capable of transmitting the mutated allele to their offspring (Figure 
1.B.d). Carriers were then crossed again with wild-type to generate 
Δ40p53+/- fish: adult Δ40p53+/- were then genotyped to characterize the 
mutated allele (Figure 1.B.e); heterozygous fish harbouring the same 
mutation were bred to generate monoallelic knock-out animals (Figure 
1.B.f). 
In detail, Cas9 protein and sgRNA were microinjected with a molar ratio 
of 2:1 into zebrafish zygotes directly into the one-cell. Survival of 
microinjected and control embryos was scored at 24hpf (Figure 1.B.a). We 
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observed no significant differences in mortality between microinjected and 
control embryos: 247/300 microinjected embryos (82.3%) and 84/100 
control embryos (84%) were alive at 24hpf. No abnormalities were observed 
in microinjected embryos: thus, we conclude that the doses of Cas9 protein 
and sgRNA used are well tolerated by zebrafish embryos and do not affect 
early development. The efficiency of our protocol was tested at 72hpf: 10 
microinjected and 4 control embryos were sacrificed for single embryo 
gDNA extraction and subsequent T7 assay. 10/10 microinjected embryos 
were positive to T7 assay; no false positive was detected in control embryos 
(Figure 2.A). Thus, we estimated that 100% of microinjected embryos could 
be considered mosaic, harbouring one or more mutations in a fraction of 
their somatic or germ cells. When mosaics are crossed with wild-type, only 
fish that harbour mutations in the germline are able to generate heterozygous 
embryos. These are considered “carriers”. To identify carriers, we crossed 10 
adult mosaic with wild-type fish. We then sacrificed one pool of 10 48hpf 
embryos born from each couple for T7 assay: considering that one couple 
resulted infertile, we found that 6/9 mosaic fish transmit the mutation to their 
offspring. Thus, we estimated that a 60% of heritability has been achieved 
(Figure 2.B). The offspring born from carrier mosaics was raised to 
adulthood. At the age of 2 months, adults were genotyped to characterize 
INDEL mutations: Δ40p53+/- fish were discriminated from wild-type by T7 
assay: out of 30 animals born from 3 different mosaic fish, 17 resulted 
heterozygous, according to the expected frequency of 50%. We then 
characterize the INDEL mutations of Δ40p53+/- fish by molecular cloning 
and sequencing of PCR amplicons of the genomic region surrounding the 
Cas9 target site. We identified 9 different INDELS:  fish born from the same 
mosaic parent can harbour different mutations, as previously observed 
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(Hwang et al., 2013b). A list of the mutations obtained is presented in Table 
1.  
We chose three different mutations to generate three monoallelic Δ40p53-
/- lines: line 1 harbour a deletion of 11bp and an insertion of 4bp that 
determines a premature STOP codon occurring 12bp downstream Δ40p53 
ATG; line 2 and 3 harbour a deletion of 7bp and an insertion of 5bp, 
respectively, that both cause a frameshift in Δ40p53 CDS. Offspring from 
the mating of Δ40p53+/- fish characterized by the same mutation resulted 
viable in all the three lines; at least 3 matings per couple were analysed and 
no developmental abnormalities was detected in the offspring of Δ40p53+/- 
fish. Lethality was assessed in the offspring of Δ40p53+/- fish and respective 
Δ40p53+/+ siblings: no significant difference was scored for at least 3 
matings per couple (data not shown). 20 embryos born from each 
heterozygous mating were collected for genotyping, in order to verify the 
presence of mutants: Δ40p53-/- embryos were present at the expected 
frequency (data not shown).  
 
p53 mRNA integrity and levels are maintained in Δ40p53-/- embryos 
Our goal is to selectively knock-out Δ40p53 without altering p53 
expression levels. This is not feasible in mice, because murine Δ40p53 is 
produced by an ATG contained in p53 exon 4. The targeted mutation of 
Δ40p53 ATG impairs the stability of p53 transcript, leading to p53 partial 
loss of function (Melis et al., 2011). Considering that we altered intron 2 of 
p53 sequence, our first issue was to investigate the presence of aberrantly 
spliced p53 mRNAs. To reveal them, three pools of 20 48hpf Δ40p53-/- 
embryos and two pools of respective Δ40p53+/+ siblings for each line were 
used for total RNA extraction and cDNA synthesis. Both Δ40p53-/- and 
Δ40p53+/+ embryos used for this and the following experiments are the 
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offspring of Δ40p53-/- and Δ40p53+/+ couples, born from Δ40p53+/- fish, so 
that the contribution of WT Δ40p53 inherited by heterozygous females is 
excluded. We amplified full-length p53 cDNA: Fw primer is located in p53 
exon 2, upstream to the mutated intron 2, while Rv primer is located on p53 
STOP codon. We detected only one band in PCR-amplified cDNA from 
Δ40p53-/- and Δ40p53+/+ sibling embryos of each line. Sequencing of PCR 
amplicons confirmed that only correctly spliced full-length p53 cDNA has 
been amplified. Levels of p53 expression were roughly quantified using β-
actin as a control: p53 expression resulted unaltered between Δ40p53-/- and 
Δ40p53+/+ sibling embryos of each line and among lines (Figure 2.C).  
In line 1, a STOP codon occurs 12bp downstream Δ40p53 ATG and a 4aa 
peptide is produced: since in the other 2 lines a longer peptide of ~100aa, 
with possible unexpected effects, is produced, we chose line 1 for further 
investigations. We asked whether p53 mRNA levels are maintained between 
Δ40p53-/- and Δ40p53+/+ siblings during development. p53 expression was 
quantified by Real-Time RT-PCR at 9 developmental stages: late mid-
blastula transition (when embryo counts 1000 cells), mid-gastrulation (50% 
epiboly), early somitogenesis (when embryo counts 1-3 somites), late 
somitogenesis (15-18 somites), 24hpf, 48hpf, 72hpf, 96hpf and 120hpf. As 
Figure 2.D shows, p53 mRNA levels result (i) comparable between Δ40p53-
/- and Δ40p53+/+ sibling embryos and (ii) higher at 1000-cell stage, 
decreasing from gastrulation and staying stable until 120hpf (Figure 2.D).  
In conclusion, our Δ40p53-/- model shows the unique opportunity to study 
the role of Δ40p53 in a context of intact p53 expression.  
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Δ40p53 and Δ113p53 expression is regulated during development and 
mRNA levels are maintained in Δ40p53-/- embryos 
We asked whether the absence of Δ40p53 affects the expression of 
Δ40p53 itself and the other short isoform of p53, Δ113p53, that has been 
already characterized in zebrafish (Chen and Peng, 2009) as the ortholog of 
the human Δ133p53 isoform. We performed a preliminary experiment 
through semiquantitative RT-PCR on a pool of Δ40p53-/- and Δ40p53+/+ 
embryos collected at the 9 already mentioned developmental stages. We 
found that: (i) mRNA levels of both the p53 isoforms are comparable 
between Δ40p53-/- and Δ40p53+/+ embryos; (ii) Δ40p53 expression is higher 
at late mid-blastula transition and gastrulation stages, decreasing rapidly 
from early somitogenesis until 120hpf, when it becomes barely detectable; 
(iii) Δ113p53 expression is low at late mid-blastula transition, reaching a 
peak at gastrulation and decreasing slightly until 120hpf (Figure 3.A). These 
results suggest that expression levels of the short isoform Δ113p53 are 
unaltered in our model.  
 
 The CDK inhibitor R-roscovitine induces Δ40p53 expression 
Since our aim is to investigate the role of Δ40p53 in the orchestration of 
p53-dependent transcriptional response to different stress agents, we 
performed a pilot experiment using the CDK inhibitor R-roscovitine. This 
drug has been already proved to be a potent p53-activating agent in 
zebrafish: the experimental conditions for its use are well set up in this 
model organism (Langheinrich et al., 2002, Lee et al., 2008, Guo et al., 
2010). Δ40p53-/- and Δ40p53+/+ embryos at mid-gastrulation stage (6hpf, 
when Δ40p53 expression is higher - Figure 3.A) were treated over-night with 
50µM and 100µM R-roscovitine, similarly to Langheinrich et al., 2002. Both 
Δ40p53-/- and Δ40p53+/+ siblings showed, at 24hpf: (i) moderate spine 
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curvature upon 50µM R-roscovitine treatment; (ii) severe developmental 
retardation and extended necrosis upon 100µM R-roscovitine treatment (data 
not shown).  
We asked (i) whether Δ40p53 expression is triggered by R-roscovitine, 
which is already known to increase Δ113p53 expression (Guo et al., 2010), 
and (ii) whether Δ40p53 has a role in the transcriptional response to R-
roscovitine. Therefore, we analysed changes in mRNA levels of p53, 
Δ40p53, Δ113p53, p21 and p66Shc genes, by Real-Time RT-PCR. Our pilot 
experiment shows that: (i) Δ40p53 expression is induced by R-roscovitine in 
a dose-dependent manner; (ii) the increase in Δ40p53 expression is higher in 
Δ40p53+/+ siblings; (iii) p53 mRNA levels are not altered by R-roscovitine, 
as previously reported (Guo et al., 2010); (iii) p21 expression is poorly 
activated by R-roscovitine, but its activation resulted higher in Δ40p53-/- 
embryos treated at the lower dose; (iv) Δ113p53 mRNA levels dramatically 
increases upon treatment in both Δ40p53-/- and Δ40p53+/+ siblings; (v) p66Shc 
expression does not vary in Δ40p53+/+ siblings, but it increases in Δ40p53-/- 
embryos in a dose-dependent manner (Figure 3.B/C). This pilot experiment 
shows that R-roscovitine is able to trigger Δ40p53 expression and that the 
absence of Δ40p53 might influence the transcriptional response to this agent.  
 
Discussion 
The N-terminally truncated isoform of p53, named Δ40p53, is involved in 
stress response in mammals (Bourougaa et al., 2010; Powell et al., 2008; 
Gambino et al., 2013) and zebrafish (Davidson et al., 2010). It has also been 
reported a role for Δ40p53 in development, since this isoform is highly 
expressed in embryonic stem cells (ESCs), where it controls the switch from 
pluripotency to differentiation (Ungewitter and Scrable, 2010). To deeply 
investigate the role of Δ40p53 in normal development and in stress response, 
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we generated the first knock-out model of Δ40p53 in zebrafish. Δ40p53-/- 
mice are not available, because murine Δ40p53 is produced by an ATG 
contained in p53 exon 4. The targeted mutation of Δ40p53 ATG impairs the 
stability of p53 transcript, leading to p53 partial loss of function (Melis et al., 
2011). For this reason, and for its extensive use in developmental biology 
studies, we chose zebrafish as a model. In this organism, Δ40p53 ortholog 
recapitulates several Δ40p53 functions previously investigated in mammals 
(Davidson et al., 2010).  
We took advantage of a Cas9 target site located in the Δ40p53-unique 
sequence (Figure 1.A) to generate three different monoallelic Δ40p53-/- lines 
(Table 1). These lines differ for the mutation that disrupts Δ40p53 coding 
sequence (CDS): line 1 harbours a deletion of 11bp and an insertion of 4bp 
that determines a premature STOP codon occurring 12bp downstream 
Δ40p53 ATG; line 2 and 3 harbour a deletion of 7bp and an insertion of 5bp, 
respectively, that cause a frameshift in Δ40p53 CDS. In each line, Δ40p53-/- 
embryos are viable, develop normally and they are not counterselected in the 
offspring born from Δ40p53+/- fish. This was expected, as both p53-/- 
(p53M214K, harbouring a dominant negative mutation of p53; Berghmans et 
al., 2005) and Δ113p53-/- (Gong et al., 2015) grow normally under standard 
conditions. Both p53-/- and Δ113p53-/- embryos show instead reduced 
transcriptional response to stress: upon γ-radiation, p53M214K embryos fail to 
undergo apoptosis, while Δ113p53-/- are unable to repair DNA double strand 
breaks.  
Since (i) CRISPR/Cas9 technology has been shown to occasionally cause 
aberrant splicing variants in targeted genes (Kapahnke et al., 2016) and (ii) 
mutations occurring in introns can lead to aberrantly-spliced mRNA 
production (Busslinger et al., 1981; Jiang et al., 2000; Davit-Spraul et al., 
2014), we asked whether the small INDELs produced in p53 intron 2 cause 
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aberrant splicing events of full-length p53 mRNA. We demonstrated that in 
our three lines, only the correctly-spliced p53 mRNA is produced (Figure 
2.C). These data indicate that any further analyses will be not compromised 
by the presence of unwanted “p53-like” products.  
We then chose line 1 for further investigations, because in this case a 4aa-
long peptide is produced, that is not expected to show unwanted or toxic 
effects. In order to attribute every phenotypic or molecular trait observed to 
the only lack of Δ40p53, we investigated p53 mRNA levels in Δ40p53-/- and 
Δ40p53+/+ siblings at 9 different developmental stages, from late mid-
blastula transition, when embryo counts 1000 cells, to 120hpf. Our results 
demonstrate that p53 mRNA levels are comparable between Δ40p53-/- and 
Δ40p53+/+ siblings and that the absence of Δ40p53 does not act on p53 
expression, at least in normal conditions. Moreover, p53 results highly 
expressed at 1000-cell stage; after gastrulation, its mRNA levels decrease 
and stay stable until 120hpf (Figure 2.D). This last finding is in agree with 
literature data: p53 expression is higher at very early developmental stages in 
mouse (Ungewitter and Scrable, 2010) and xenopus (Tchang et al., 1993) 
embryos.  
Δ40p53 is considered an embryonic isoform of p53, beingly mostly 
expressed immediately after implantation in the mouse embryo (Ungewitter 
and Scrable, 2010). Therefore, we asked how Δ40p53 is regulated during 
zebrafish development. We also analysed Δ113p53 mRNA levels in Δ40p53-
/- and Δ40p53+/+ siblings, since the lack of Δ40p53 might affect 
transcriptional levels of Δ113p53. This isoform, in fact, is transcribed by its 
own promoter located in p53 intron 5 (Chen and Peng, 2009), and it is 
known that, in both human and zebrafish, p53 itself regulates the expression 
of this short isoform (Aoubala et al., 2011; Guo et al., 2010). We obtained 
preliminary data by semiquantitative RT-PCR showing that Δ40p53 is 
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mostly expressed until gastrulation stage. On the contrary, Δ113p53 
expression is very low at 1000-cell stage, it reaches a peak at gastrulation 
and decreases slightly until 120hpf. Moreover, mRNA levels of these two 
isoforms are comparable between Δ40p53-/- and Δ40p53+/+ siblings (Figure 
3.A). These findings suggest that: (i) the two short p53 isoforms might play 
different roles in embryonic development; (ii) their mRNA levels are not 
altered by the absence of Δ40p53, at least in normal conditions. However, 
these data have to be confirmed by Real-Time RT-PCR assays and western 
blot, in order to demonstrate that expression of the three p53 isoforms is not 
altered also at a protein level. Finally, the fact that Δ40p53 mRNA levels are 
maintained in the Δ40p53-/- line is not surprising. The nonsense-mediated 
decay (NMD) mechanism, which is responsible for the degradation of 
mRNAs harbouring premature non-sense mutations, is conserved in 
zebrafish (Wittkopp et al., 2009), but it has been reported that only some 
CRISPR/Cas9-mediated frameshift mutations lead to a reduced level of 
targeted-gene mRNA (Li et al., 2014; Mehrabian et al., 2014). Most 
importantly, it has been demonstrated that mRNA harbouring premature 
STOP codons located in proximity to the initiation codon escape NMD 
(Perrin-Vidoz et al., 2002; Inacio et al., 2004). Given that the premature 
STOP codon harboured by the Δ40p53-/- line is located only 9 nucleotides 
downstream to the ATG, the mutated Δ40p53 mRNA is likely to escape 
NMD. 
The major advantage of our Δ40p53-/- model resides in the possibility of 
investigating the role of Δ40p53 in stress response in vivo. Zebrafish 
embryos are a rapid tool to test a wide range of different stress agents. As a 
pilot assay, we decided to treat Δ40p53-/- and Δ40p53+/+ siblings with R-
roscovitine, a cycline-dependent kinase inhibitor that preferentially inhibits 
CDK2, CDK7 and CDK9. R-roscovitine is a potent p53 activating agent, 
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being responsible for inhibition of MDM2 expression (Lu et al., 2011). We 
chose R-roscovitine because it has been extensively used by several groups 
to induce p53-dependent response in zebrafish. It is known that an over-night 
treatment with 50µM R-roscovitine induces: (i) developmental abnormalities 
(Langheinrich et al., 2002); (ii) p53 stabilization (Lee et al., 2008); (iii) 
overexpression of several p53 target genes, including Δ113p53, p21 and 
puma (Guo et al., 2010). Moreover, R-roscovitine triggers mitochondrial 
apoptosis: this drug induces a post-translational modification of p53 that 
modulates its transcriptional activity, leading to mitochondrial membrane 
depolarization and releasing of cytochrome c (Wasierska-Gadek et al., 
2005).  
We obtained preliminary data by treating Δ40p53-/- and Δ40p53+/+ siblings 
at gastrulation stage with 50µM and 100µM R-roscovitine and analysing 
changes in mRNA levels of p53, Δ40p53, Δ113p53, p21 and p66Shc by 
qPCR. We included p66Shc since, interestingly, it takes part in p53-dependent 
apoptosis upon different stress (Migliaccio et al., 1999; Gambino et al., 
2013). p66Shc triggers mitochondrial swelling through cytochrome c 
oxidation (Giorgio et al., 2005), as R-roscovitine does by modulating p53 
transcriptional activity. Furthermore, recent evidence suggests that p53 
might directly enhance p66Shc expression by binding to its promoter upon 
treatment with the cell cycle progression inhibitor cyclophosphamide (Xiong 
et al., 2016). 
Our pilot experiment shows that Δ40p53 expression is induced by R-
roscovitine: in particular, Δ40p53 appears to be strongly increased by 
treatment with the higher dose. Δ40p53 expression is higher in Δ40p53+/+ 
then in Δ40p53-/- embryos: this might be due to the absence of Δ40p53 
protein and the lack of a hypothetic positive-feedback mechanism involved 
in Δ40p53 transcriptional regulation. p53 mRNA levels are stable, while 
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Δ113p53 expression dramatically increases, as previously shown (Guo et al., 
2010) in both Δ40p53-/- and Δ40p53+/+ embryos. p21 expression does not 
increase in a dose-dependent manner: this might be due to the fact that the 
higher R-roscovitine dose is associated with a very severe phenotype and, 
thus, with apoptosis and not cell senescence. p66Shc expression does not vary 
in Δ40p53+/+ sibling, but surprisingly it increases in Δ40p53-/- embryos in a 
dose-dependent manner. These preliminary data suggest the intriguing 
hypothesis that the absence of phenotypic differences between treated 
Δ40p53-/- and Δ40p53+/+ siblings might be the result of a mechanism of 
genetic compensation. Since Δ40p53 is upregulated by R-roscovitine 
treatment, it might be involved in the transcriptional response to this stress 
agent. The absence of Δ40p53 might be compensated by the upregulation of 
other p53-related pro-senescence or pro-apoptotic factors, such p66Shc.  
Δ40p53 has been shown to be involved, in vitro, in the transcriptional 
regulation of a mitotic signature whose downregulation triggers cell cycle 
arrest specifically upon protein damage (Bourougaa et al., 2010; Gambino et 
al., 2013). We will evaluate in vivo: (i) the contribution of Δ40p53 in 
response to protein damage; (ii) whether Δ40p53 is involved also in DNA 
damage response and (iii) whether and how the transcriptional response to 
protein and DNA damage differs in terms of genes involved in a Δ40p53-/- 
context. To address our questions, Δ40p53-/- and Δ40p53+/+ siblings will be 
treated with known p53-activating agents, such as UV (Zhao et al., 2012) or 
doxorubicin (Henriques et al., 2013), to induce primarily DNA damage, and 
with H2O2 and or the proteasomal inhibitor MG132 (Bretaud et al., 2007), to 
induce primarily protein damage. The transcriptome of Δ40p53-/- will be 
investigated by RNA-sequencing analysis.  
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Figure 1 
 
 
 
 
Unravelling the p53/p66Shc pathway in vivo  
 
108 
 
 
 
 
Figure 1. Pipeline used to generate the Δ40p53-/- lines. A. Zebrafish p53 
genomic locus consists of 11 exons. Full-length p53 ATG is located in exon 2. 
When the following intron is partially retained (as described in Davidson et al., 
2010, green box), a STOP codon causes premature end of FLp53 translation. The 
downstream Δ40p53 ATG is used for Δ40p53 translation: this isoform has a 
unique N-terminal domain but lacks the first p53 transactivation domain. It shares 
all the other functional domains with p53. An internal promoter contained in the 
fourth intron (violet circle) drives the transcription of Δ113p53 isoform, whose 
5’UTR is located in intron 4 (blue box) and in exon 5, where Δ113p53 ATG is 
located. All the p53 isoforms end with the STOP codon located in exon 11. To 
specifically knock-out the Δ40p53 isoform, we found a Cas9 target site (in green, 
PAM sequence in red). The target site is very close to Δ40p53 ATG (underlined): 
this determines the complete loss of function of the mutated Δ40p53 allele. B. 
Wild-type zebrafish embryos are microinjected with the Cas9 protein/sgRNA 
complex directly into the one-cell (a). gDNA is extracted from single 
microinjected embryos to detect the presence of INDEL mutations via PCR 
amplification of the Δ40p53 locus and T7 assay (b). Microinjected embryos are 
maintained until sexual maturity: mosaic fish harbour mutations in a fraction of 
their cells. Mutations are inheritable only if present in the germline of mosaic 
fish, that can be so considered «carriers». When mosaics are crossed with wild-
type, only fish that harbour mutations in the germline are able to generate 
heterozygous embryos. To select carriers, pools of 10 embryos born from the 
mating of mosaic with wild-type fish are used for gDNA extraction, PCR 
amplification of the Δ40p53 locus and T7 assay (c). Carrier mosaic fish are 
crossed again with wild-type and their offspring is raised to adulthood (d). Fish 
born from the mating of carrier mosaics and wild-type are expected to be 
heterozygous with a frequency of 50%. They are subjected to gDNA extraction, 
PCR amplification of the Δ40p53 locus and T7 assay to identify heterozygosity. 
PCR amplicons from Δ40p53+/- fish are cloned and sequenced to characterize the 
mutations (e). Δ40p53+/- fish harbouring the same mutation are bred. The 
resulting offspring consists of Δ40p53+/+, Δ40p53+/- and Δ40p53-/- fish. Fish are 
raised to adulthood for genotyping. Knock-out fish harbouring the same mutation 
are bred to generate homozygous Δ40p53-/- lines (f).  
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Figure 2 
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Figure 2. A. Efficiency of Cas9 specific cleavage upon microinjection of Cas9 
protein/sgRNA: 10 embryos, that were microinjected directly into the one-cell 
with the Cas9 protein/sgRNA complex, and 4 control embryos were used for 
gDNA extraction. The genomic region surrounding the Cas9 target site was 
amplified by PCR and PCR product was denatured/renatured and digested with 
T7 endonuclease 1 (I: microinjected embryos; NI: control embryo; -: untreated 
PCR product; +: treated PCRproduct; C+: heterozygous gDNA was used as 
positive control). B. Heritability of INDEL mutations. 10 mosaic fish were 
crossed with wild-type and one pool of 10 embryos per couple was used for 
gDNA extraction. The genomic region surrounding the Cas9 target site was 
amplified by PCR and PCR product was denatured/renatured and digested with 
T7 endonuclease 1 (-: untreated PCR product; +: treated PCR product; C+ and C-
: gDNA from mosaic and wild-type fish were used as positive and negative 
controls). C. Full-length p53 expression in the three Δ40p53-/- lines. Three 
pools of 20 48hpf Δ40p53-/- embryos and two pools of respective siblings for 
each line were used for total RNA extraction and cDNA reverse transcription. 
The presence of aberrant p53 transcripts were investigated by RT-PCR of full-
length p53. β-actin was used to assess the quality of cDNA and to allow rough 
quantification of p53 mRNA levels. Only the band corresponding to the correctly 
spliced full-length p53 mRNA is present in both knock-outs and siblings of each 
line. mRNA levels of p53 are comparable between knock-outs and siblings and 
among the three lines. D. p53 qPCR expression levels in line 1 at different 
developmental stages. Three pools of 30-50 embryos for each developmental 
stage were used for total RNA extraction and cDNA reverse transcription. We 
considered 9 stages: late mid-blastula transition (1000-cell embryo), gastrulation 
(Ga, 50% epiboly), early somitogenesis (TB), late somitogenesis (So), 24hpf, 
48hpf, 72hpf, 96hpf and 120hpf. Real-Time RT-PCR with p53-specific primers 
(that exclude the amplification of Δ40p53 and Δ113p53) shows that p53 mRNA 
levels are comparable between Δ40p53-/- and Δ40p53+/+ siblings at each 
developmental stage. 
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Table 1 
 
 
Table 1. List of the INDEL mutations characterized in Δ40p53+/- fish. INDEL 
mutations were characterized by molecular cloning and following sequencing of 
the PCR products obtained by amplification of the Δ40p53 genomic region 
surrounding the Cas9 target site. Red dots: established Δ40p53-/- lines; red box: 
the Δ40p53-/- line used for studies on gene expression and stress response.  
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Figure 3 
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Figure 3. A. Δ40p53 and Δ113p53 mRNA levels in line 1 at different 
developmental stages. One pool of 30-50 embryos for each developmental stage 
was used for total RNA extraction and cDNA reverse transcription. We 
considered 9 stages. 1: late mid-blastula transition (1000-cell embryo); 2: 
gastrulation (50% epiboly); 3: early somitogenesis; 4: late somitogenesis; 5: 
24hpf; 6: 48hpf; 7: 72hpf; 8: 96hpf; 9: 120hpf. Semiquantitative RT-PCR with 
primers specific for each isoform shows that mRNA levels of both Δ40p53 and 
Δ113p53 are comparable between Δ40p53-/- and Δ40p53+/+ embryos. Δ40p53 
expression rapidly decreases after gastrulation, while Δ113p53 is barely 
detectable at 1000-cell stage; its expression reaches a peak at gastrulation and 
then slightly decreases. B. Real-Time RT-PCR fold changes of p53-target 
genes in Δ40p53-/- embryos upon 50µM R-roscovitine treatment. Δ40p53-/- 
(KO) and Δ40p53+/+ (SB) embryos at gastrulation stage were treated over-night 
with 50µM R-roscovitine. They were collected at 24hpf for total RNA extraction 
and cDNA reverse transcription. Δ40p53 expression is triggered by R-
roscovitine. Interestingly, p66Shc expression is activated only in Δ40p53-/- 
embryos. As previously shown, p53 expression is stable, while Δ113p53 is 
strongly activated in both KO and SB embryos. Topoisomerase 1 was used as 
housekeeping gene. The 2(-ΔΔCt) method was used for relative quantification of 
gene expression. Values obtained for untreated SB embryos were used as 
calibrators for each gene.  C. Real-Time RT-PCR fold changes of p53-target 
genes in Δ40p53-/- embryos upon 100µM R-roscovitine treatment. Δ40p53-/- 
(KO) and Δ40p53+/+ (SB) embryos at gastrulation stage were treated over-night 
with 100µM R-roscovitine and then collected as previously described. Δ40p53 
expression is strongly induced by R-roscovitine and it results increased in 
Δ40p53+/+ embryos. Again, p66Shc expression results strongly activated only in 
Δ40p53-/- embryos. p53 expression is stable, p21 expression is poorly increased, 
while Δ113p53 is dramatically activated in both KO and SB embryos. 
Topoisomerase 1 was used as housekeeping gene. The 2(-ΔΔCt) method was used 
for relative quantification of gene expression. Values obtained for untreated SB 
embryos were used as calibrators for each gene.    
Unravelling the p53/p66Shc pathway in vivo  
 
114 
 
Supplementary material 
Primer list & references 
 
 
 
M13Fw GTAAAACGACGGCCAGT  Burg et al., 2016 
CustomRv CGCTAGCTAATACGACTCACTATAGGTCGAACGTATTGTTTATCGTTTTAGA
GCTAGAAATAG 
T7Fw GCTAGCTAATACGACTCACT Burg et al., 2016 
sgRNARv AAAAGCACCGACTCGGTG Burg et al., 2016 
 Forward Reverse 
Δ40g GTAAAACGACGGCCAGT CGATCCCGGCAAGTACTC 
wt GCATCTGTCGAACGTATTGTTTA CTGAGCCTAAATCCATGATCG 
mut TTAAGATGCATCTGTATTGAACG CTTCTGAGACAATTGAAAAGGAAG 
FLp53 GGTCGGCAAAATCAATTCTTG ATCAGAGTCGCTTCTTCCTTC 
βact TGTTTTCCCCTCCATTGTTGG TTCTCCTTGATGTCACGGAC 
qp53 GGGAGAAGAATTTGATTATTCAGC ATTCAGGTCCGGTGAATAAGTG 
qΔ40 CTGGAGTTCTTTGTTTGAGCTTC ATTCAGGTCCGGTGAATAAGTG 
qΔ113 ATATCCTGGCGAACATTTGGAG CATCTGCGGACCACTTCAG 
qp21 GTTTCAGCTCTTGCAGAAGC CGTTTCTGCTGCTTTTCCTG 
qp66 CACCACCTTATGCTCCTTCTTC TTCCGAGGACTCTCCCAAA 
qEF1 ACATCAAGAAGATCGGCTACAA CAGGCTTGAGGACACCAG 
qTop1 GGACCATTCCCACAACGATTC TGTGTTCGCTGTTGCTGTAC 
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In this second section of Part III, we show the findings obtained about 
two branches of this project, aimed at investigating the functional 
conservation of p53, p44 and p66Shc in Nothobranchius furzeri and revealing 
the role of p66Shc in embryonic development, taking advantage of Danio 
rerio. These data will be part of two short communications. 
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Preliminary investigation on the conservation of 
p66Shc and p53/p44 in Nothobranchius furzeri 
One of our aims is to generate a genetic model of p44 and/or p66Shc 
overexpression or ablation in the short-living vertebrate Nothobranchius 
furzeri, in order to characterize the role of p44 in stress response in aging. 
Therefore, we first focused on investigating the functional conservation of 
p44 itself, and its partners p53 and p66Shc, in this organism. Contrary to 
zebrafish, the developmental biology of this killifish has not been explored; 
transient manipulation of gene expression, whole-mount in situ 
hybridization and pharmaceutical treatment of embryos have not been 
implemented yet. Thus, we chose to take advantage of mammalian cell 
cultures derived from p53-/- and p66Shc-/- mice to study the functional 
conservation of N. furzeri orthologs of p44, p53 and p66Shc through 
heterologous complementation experiments.  
1. Materials and Methods 
1.1  Nothobranchius furzeri maintenance 
 
Fish of the Nothobranchius fuzeri strain MZM 04/10 are maintained in a 
commercial system (“Stendalone”, Tecniplast). Each male is maintained in a 
3L tank and group of 3-4 females are maintained in 8L tanks. Water 
temperature is set at 26.5°C, pH at 6.5 and conductivity at 300µS. The 
circadian rhythm imposed is 14 hours of light and 10 hours of darkness. 
Adult fish are fed twice a day with frozen bloodworms (Ocean Nutrition). 
Unravelling the p53/p66Shc pathway in vivo  
 
123 
 
Adult fish are bred twice a week: N. furzeri embryos are maintained in 
system water with 0.05% methylene blue for ~two weeks, then they are 
moved into humid peat moss until ready to be hatched. Embryos are 
hatched in small tanks with peat moss and system water at 8-10°C. After 
hatching, Nothobranchius larvae are fed twice a day with living brine 
shrimps (MBK Installations) until they are two-week old. Then, larvae are 
fed for one week with a mix of brine shrimps and chopped bloodworms and 
for two weeks, twice a day, with chopped bloodworms. 
1.2 Molecular cloning of p66Shc, p53 and p44 
Total RNA was extracted from organs of male adult fish with Qiazol 
Reagent (QIAGEN) according to the manufacturer instruction. After 
extraction, 30µg of total RNA were treated with 6U of TURBO DNase 
(Ambion) for 30’ at 37°C and then column purified (Quick-RNA MiniPrep kit, 
Zymo Research). 1µg of total RNA was then retrotranscribed 1h at 42°C for 
cDNA synthesis using 0.5µg of oligodT (Invitrogen), 160U of ImProm-II 
Reverse Transcriptase (Promega), 3mM MgCl2, 0.3mM dNTPs and 20U of 
RNAse Inhibitor (NEB).  About 100ng of cDNA were used for RT-PCR to 
amplify full-length p66Shc, p53 and p44 with the primers listed in the table 
below. A 30-cycle touchdown RT-PCR was run as follows: 2U of Phusion 
High Fidelity DNA Polymerase (NEB), 0.2mM dNTPs and 0.5µM each primer 
with an annealing temperature decreasing from 63°C to 55°C. Primer 
sequence was determined using the N. furzeri transcriptome browser 
(Petzold et al., 2013; http://nfintb.leibniz-fli.de/nfintb/) searching for N. 
furzeri shc1 and p53 coding sequences. Primers to amplify the putative N. 
furzeri p44 ortholog were determined using the sequence of genomic p53 
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locus kindly provided by Dr Alessandro Cellerino. To allow subcloning into 
the retroviral pBABE-Puro:flag vector (Addgene #1764, previously modified 
with the insertion of a flag tag at the C-terminus of the multicloning site) we 
designed primer for restriction enzyme cloning. Addition of 3’-A overhangs 
to PCR products was performed using 1 U of Taq Polymerase (QIAGEN) for 
30’ at 72°C. Then PCR amplicons were ligated into the pCR 2.1-TOPO vector 
(Invitrogen) following the manufacturer instructions. Ligation reactions 
were used to transform TOP10 competent cells (Thermo Fisher Scientific) 
according to the manufacturer instructions. Plasmid DNA from 2ml of over-
night mini-cultures was extracted with Nucleospin Plasmid Kit (Macherey-
Nagel) and sequenced by Sanger sequencing. Sequences were then 
analysed using Chromas lite software (Technelysium).  
 
N. furzeri p66Shc cDNA was then subcloned into the pBABE-Puro:flag 
vector by exciding the insert via BamHI/HindIII restriction enzymes (NEB), 
gel extraction (QIAquick gel extraction kit) and O.N. ligation into the 
destination vector. N. furzeri p53 and p44 cDNA were subcloned into the 
pBABE-Puro:flag vector using BamHI/EcoRI restriction enzymes (NEB). 
 
cDNA Forward primer Reverse primer 
Np66Shc CAGATACTTGAGTGTCCTTCC GGCCTTGCGCTCCACTG 
Np53 AGACAGAAGATATGGAGGACTCTG CTAATCGCTGTCACTCCGGTC 
Np44 GGCTGTTTGATTAATGCAAGT CTAATCGCTGTCACTCCGGTC 
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1.3  Cell culture, retroviral infection of p66Shc-/- and p53-/- 
MEFs and treatments 
Mouse embryonic fibroblasts (MEFs) were isolated from 13.5 day-old 
p66Shc-/- or p53-/- embryos according to standard procedures. MEFs were 
cultured in DMEM supplemented with 10% foetal bovine serum, 100µg/ml 
streptomycin and penicillin, 2mM L-glutamine and incubated at 37°C, 5% 
CO2 and 20% O2. Retroviruses were produced by transfecting Phoenix-Eco 
cells with 10µg of pBABE-Puro:flag constructs. After 48h, supernatants were 
collected and filtered with a 0.45µm filter. Then 5ml of each supernatant 
was supplemented with 50µg of polybrene and added to early passage 
MEFs. Each supernatant was removed three hours later and a second cycle 
of infection was repeated. 48 hours after infection, selection was 
performed by adding 2µg/ml puromycin. Infected MEFs were maintained in 
selection for five days and then used for further experiments. To perform 
treatments, MEFs were washed twice with PBS and then incubated O.N. in 
DMEM medium containing 400µM H2O2 (Sigma-Aldrich) or 0.25µg/ml 
doxorubicin (Sigma-Aldrich). 
1.4  Western blotting 
Cells were lysed by scraping with 2ml of lysis buffer (50mM Tris pH8.0, 
5mM EDTA, 150mM NaCl, 0.5% Nonidet P-40 and Mini Protease Inhibitor 
Cocktail – Sigma-Aldrich). Lysates were kept 30’ on ice and centrifuged for 
15’ at 13000rpm and 4°C. Protein concentration in supernatants was 
determined with the Bio-Rad DC protein assay. 30µg of total protein lysate 
for each sample was supplemented with 5x Laemmli buffer (1.5M Tris-HCl 
pH 6.8, 10% SDS, 50% glycerol, 25% β-mercaptoethanol, 0.01% 
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bromophenol blue 0,01%), boiled for 3’, separated on SDS-polyacrylamide 
gel and then transferred at 100V for 1h and 15’ to a 0.45µm nitrocellulose 
membrane. Blots were then incubated 1h in 5% non-fat dried milk in TBST. 
α-Shc1 polyclonal antibody (BD Transduction) was diluted 1:1000 and α-
Flag M2 monoclonal antibody (Sigma-Aldrich) was diluted 1:2000 in milk 
and incubated O.N. at 4°C.  Then blots were washed in TBST buffer and 
incubated 1h at room temperature with peroxidase-conjugated goat anti-
mouse IgG and anti-rabbit IgG (Amersham Biosciences GE Healthcare) 
diluted 1:10000 in milk. Chemiluminescence was detected with Clarity 
Western ECL Substrate (Bio-Rad).  
1.5  Senescence assay on MEFs 
Senescent MEFs were identified by their ability to positive-stain for acid 
β-galactosidase at pH 6. The Senescence β-Galactosidase Staining Kit (Cell 
Signalling) was used to reveal β-galactosidase activity according to the 
manufacturer instructions. 
1.6  Real-Time RT-PCR 
Untreated and treated MEFs were washed and scraped in PBS and briefly 
centrifuged. Pelleted cells were conserved at -80°C. Total RNA was 
extracted from MEFs with Qiazol Reagent (QIAGEN), according to the 
manufacturer instructions. After extraction, 30µg of total RNA were treated 
with 6U of TURBO DNase (Ambion) for 30’ at 37°C and then column purified 
(Quick-RNA MiniPrep kit, Zymo Research). 1µg of total RNA was then 
retrotranscribed 1h at 42°C for cDNA synthesis using 0.5µg of a primer mix 
consisting in oligodT and random primers (Invitrogen) in 3:1 ratio, 160U of 
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ImProm-II Reverse Transcriptase (Promega), 3mM MgCl2, 0.3mM dNTPs 
and 20U of RNAse Inhibitor (NEB). Expression changes of the p53/p66Shc-
dependent G2/M transition genes were investigated using the TaqMan® 
Gene Sets technology, a high-throughput Real Time RT-PCR approach 
exploiting a custom-designed Applied Biosystems Micro Fluidic Card. A 
complete list of the p53/p66Shc-dependent G2/M transition genes can be 
found in Gambino et al., 2013. The Quantitative PCR Facility (Cogentech) 
performed the reactions in triplicate. The 2(-∆∆CT) method was used for 
relative quantification of gene expression; values relative to untreated WT 
MEFs were used as calibrators. 
2. Results 
2.1  Nothobranchius p66Shc is expressed in adult tissues 
We used Nothobranchius furzeri transcriptome browser (Petzold et al., 
2013; http://nfintb.leibniz-fli.de/nfintb/) to identify the ortholog of shc1. 
Sequence analyses revealed that both the isoforms of shc1 are present in 
this fish. To confirm that the p66Shc isoform of shc1 is expressed in adult 
tissues, we performed RT-PCR on N. furzeri brain, heart, intestine, liver and 
muscle (pools of 4 organs extracted from 4 adult males). We found that a 
PCR product of the expected length has been amplified in all the organs and 
tissues analysed (Figure 1.A) Molecular cloning of PCR products and 
sequence analyses revealed that this amplicon corresponds to the N. furzeri 
ortholog of p66Shc (Np66Shc) that shows conservation with mammalian 
p66Shc (Priami et al., 2015).  We than asked whether this cDNA is functional: 
to confirm that a protein of the expected molecular weight is produced by 
utilization of the putative p66Shc ATG, we subcloned Np66Shc into the 
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retroviral pBABE-Puro:flag vector and infected mouse embryonic fibroblasts 
(MEFs) derived from p66Shc-/-  mice with this construct. Western blot on 
protein lysates from p66Shc-/- MEFs using the α-Shc1 antibody that recognise 
mammalian Shc1 isoforms (Gambino et al., 2013) shows that a 66KDa band 
is present in protein lysate from p66Shc-/- MEFs reconstituted with Np66Shc 
cDNA (Figure 1.B).  
2.2  Nothobranchius p53 and p44 partially recapitulate 
mammalian p53/p44 functions in oxidative stress 
response 
We identified the putative p44 ortholog by sequence analysis of the 
Nothobranchius furzeri p53 genomic locus. The mechanism we propose for 
p44 production in N. furzeri is the alternative splicing of p53 intron 2: in this 
Figure 1. Nothobranchius p66Shc is expressed in adult tissues. (A) RT-PCR on total 
RNA extracted from pools of organs and tissues extracted from 4 adult males. The 
expected ~1800bp band, corresponding to the putative p66Shc ortholog cDNA, is 
present for all the tissues. (B) Western blot with α-Shc1 antibody on protein 
lysates of WT MEFs and p66Shc-/- MEFs reconstituted with empty vector (+EV) and 
Nothobranchius p66Shc (+Np66Shc). A protein of the expected 66KDa molecular 
weight is present in the protein lysate of p66Shc-/- MEFs reconstituted with Np66Shc. 
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intron, we found an in-frame STOP codon that leads to premature 
interruption of p53 translation. Partially overlapped to this STOP codon, an 
ATG, in-frame with the downstream p53 exons, is present. The utilization of 
this ATG leads to the production of a N-terminal isoform of p53, where the 
first transactivation domain (TAD) is substituted with a different N-terminal 
aminoacidic sequence. This mechanism has been described also by 
Davidson and colleagues for the production of the p44 ortholog in zebrafish 
(Davidson et al., 2010). Notably, N-terminal p44-specific aminoacidic 
sequences of N. furzeri and zebrafish do not show significant homology 
(Figure 2), suggesting that the p44-specific N-terminal domain present in 
these two teleost fish species might not have an impact on p44 function. 
Using specific primers, we were able to amplify by RT-PCR the full-length 
cDNA sequence of the putative p44 N. furzeri ortholog, which resulted 
expressed at low levels in several adult tissues (brain, heart, intestine and 
testes; Figure 3.A). Sequence analysis confirmed our predictions on p44 
cDNA structure, which shares all the p53 exons from exon 3 and has a 
unique N-terminal sequence.  
Figure 2. Multiple alignment of the N-terminal domains of human, mouse, 
Nothobranchius and zebrafish p44 protein. Human (Hsa), mouse (Mmu), 
Nothobranchius (Nfu) and zebrafish (Dre) p44 have been aligned using Clustal 
Omega: Nothobranchius and zebrafish p44-specific amino-acidic sequences do not 
show significant homology.  
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We asked whether N. furzeri p44 differs from p53 in its functions, in 
particular in response to oxidative stress (OS). The lack of a commercial 
antibody working on N. furzeri p53/p44 did not allow us to detect the 
endogenous protein. To address our question, we cloned both 
Nothobranchius p53 (Np53) and p44 (Np44) cDNA into the pBABE-Puro:flag 
retroviral vector, to take advantage of the flag tag for protein detection. We 
performed heterologous complementation experiments in MEFs derived 
from p53-/- mice and reconstituted with Np53 or Np44. Western blots with 
the α-flag antibody on protein lysates from Phoenix-Eco cells, used for 
retroviral packaging, and p53-/- MEFs reconstituted with fish proteins show 
that both Np53 and Np44 are expressed by mammalian cells (Figure 3.B). To 
investigate whether fish proteins are able to enter the mammalian 
machinery and to induce stress response, we treated p53-/- MEFs O.N. with 
400µM hydrogen peroxide (to induce OS damage to macromolecules) or 
0.25µg/ml doxorubicin (to induce specifically genotoxic stress - GS). We 
then investigated cell senescence upon treatments after seven days of 
recovery in standard medium by senescence-associated β-galactosidase 
staining. Results of this preliminary experiment show that (i) reconstitution 
with empty pBABE-Puro:flag vector is not associated with increased cell 
senescence upon treatments; (ii) reconstitution with Np53 resulted in a 
dramatic induction of cell senescence upon treatments but also at basal 
conditions; (iii) reconstitution with Np44 resulted in increased cell 
senescence only upon treatments and in particular upon OS (Figure 3.C).  
Moreover, we investigated whether Np53 and Np44 are able to 
recapitulate mammalian p53 and p44 functions in terms of transcriptional 
regulation to stress response: we performed Real Time RT-PCR on total RNA 
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extracted from wild-type MEFs and p53-/- MEFs reconstituted with fish 
proteins and treated with H2O2 or doxorubicin. We analysed expression 
changes of p21 and 31 genes which transcriptional regulation depends on 
p53. These 31 genes are involved in the G2/M transition phase of the cell 
cycle and they are downregulated specifically upon OS in MEFs. This 
downregulation is increased in MEFs derived from Tgp44 mice, which 
overexpress the p44 isoform of p53 (Gambino et al., 2013).  Results of this 
preliminary experiment show that: (i) G2/M genes are downregulated in 
wild-type MEFs upon both the treatments as expected (Gambino et al., 
2013); (ii) G2/M genes are not downregulated upon treatments in p53-/- 
MEFs reconstituted with empty vector or Np53; (iii) reconstitution with 
Np44 is associated with the downregulation of G2/M genes upon treatment 
with H2O2 but not doxorubicin (Figure 3.D). Moreover, p21 results 
upregulated in wild-type MEFs and in p53-/- MEFs reconstituted with Np53 
upon both the treatments. Reconstitution with Np44 leads to mild p21 
upregulation only upon treatment with doxorubicin (Figure 3.E). Overall, 
this preliminary experiment suggests that Np53 is able to induce cell 
senescence upon both OS and GS via p21 upregulation, but not 
downregulation of G2/M transition genes. On the contrary, Np44 induces 
cell senescence upon OS via downregulation of G2/M genes. 
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Figure 3. Nothobranchius p53 and p44 partially recapitulate mammalian 
functions. (A) RT-PCR on total RNA extracted from pools of organs and tissues of 4 
adult males. The expected ~1200bp band, corresponding to the putative p44 
ortholog cDNA is present in brain, heart, liver and testes (red asterisks). (B) 
Western blot with α-flag antibody on protein lysates of Phoenix-Eco and p53-/- 
MEFs reconstituted with empty vector (+EV), Np53 or Np44. Proteins of the 
expected ~50KDa and ~44KDa molecular weight are present in lysates from cells 
reconstituted with the retroviral constructs containing Np53 or Np44 cDNA. (C) 
Senescence-associated β-galactosidase activity in p53-/- MEFs reconstituted with 
EV, Np53 or Np44 and treated with H2O2 or doxorubicin. Np53 induces cell 
senescence also at basal conditions, while Np44 induces cell senescence only 
upon stress and in particular upon OS. (D) Box plot representation of Real-Time 
RT-PCR fold changes of 31 p53/p66Shc-dependent G2/M transition genes in WT 
MEFs and p53-/- MEFs reconstituted with EV, Np53 or Np44 and treated with H2O2 
or doxorubicin. Np53 does not induce downregulation of G2/M genes while Np44 
induces their downregulation only upon OS. (E) Real-Time RT-PCR fold-changes of 
p21 in WT MEFs and p53-/- MEFs reconstituted with empty vector EV, Np53 or 
Np44 and treated with H2O2 or doxorubicin. Np53 induces p21 upregulation upon 
both the treatments, while Np44 induces mild p21 upregulation only upon 
treatment with doxorubicin.  
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3. Discussion 
p66Shc is the longest isoform encoded by the shc1 locus. The shortest 
isoforms, p52Shc and p46Shc are involved in Ras signalling. These two 
isoforms are phosphorylated by active tyrosine kinase receptors and drive 
the MAPK (Mitogen-Activated Protein Kinase) cascade and thus cell 
proliferation (Pelicci et al., 1992). The third isoform, p66Shc, is translated 
from a different mRNA. p66Shc contains the entire p52Shc/p46Shc sequence 
plus an additional amino-terminal region (Ventura et al., 2002). p66Shc, 
contrary to p52Shc/p46Shc, does not contribute to stimulate cell proliferation 
(Migliaccio et al., 1997). p66Shc is involved in oxidative stress response (OS): 
OS activates p66Shc that directly promotes apoptosis (Giorgio et al., 2005). 
The p66Shc-/- mouse model, generated in 1999, is a genetic model of healthy 
aging. It has been demonstrated that the deletion of p66Shc improves 
general health in the aging mouse, being implicated in increased resistance 
to OS-induced apoptosis (Migliaccio et al., 1999).  p66Shc deletion also 
ameliorates of the phenotype of different mouse models of human 
diseases, such as (i) acute ischemia (Zaccagnini et al., 2004), (ii) diabetes 
(Menini et al., 2006), (iii) age-dependent decrease of endothelial functions 
(Francia et al., 2004), (iv) hepatic steatosis (Koch et al., 2008) and (v) 
Alzheimer disease (Derungs et al., 2016). Nevertheless, all the molecular 
mechanisms underlying p66Shc functions in aging are far of being deeply 
understood. Our aim is to further investigate p66Shc genetics taking 
advantage of the short-living vertebrate N. furzeri. This teleost fish is an 
emerging model in which the generation of transgenic lines (Valenzano et 
al., 2011; Allard et al., 2013) and CRISPR/Cas9-mediated knock-out lines 
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(Harel et al., 2015) are feasible, as well as screenings on compounds 
affecting lifespan and healthspan (Valenzano et al., 2006).  
We used the N. furzeri transcriptome browser (Petzold et al., 2013; 
http://nfintb.leibniz-fli.de/nfintb/) to identify the ortholog of shc1. We were 
able to clone the N. furzeri ortholog of p66Shc (Np66Shc) and proved that it is 
expressed in several adult tissues (Figure 1.A). Our sequence analyses show 
that the aminoacidic domains important for p66Shc to exert its functions are 
conserved in N. furzeri. This is the basis for further functional analyses: 
heterologous complementation experiments in p66Shc-/- mammalian cells 
will be useful to elucidate whether Np66Shc is able to initiate OS response, 
as in mammals. Further investigations include in vivo analyses of Np66Shc 
expression changes under different environmental conditions or stresses 
and the generation of a genetic model of Np66Shc overexpression or 
ablation.  
The tumour suppressor p53 is involved, as p66Shc, in lifespan and aging 
modulation: when p53 activity in enhanced, but the mechanisms that 
ensure a normal regulation of its turn-over are maintained, p53 promotes 
longevity. On the contrary, when p53 is constitutively active, it promotes 
aging without an increase in cancer susceptibility. Therefore, the p53-
dependent transcriptional response is fine-tuned to avoid proliferation of 
damaged, potentially cancerous, cells but also to avoid the loss of stem cell 
compartments and preserve tissue homeostasis (Feng et al., 2011; 
Reinhardt and Schumacher, 2012).  
p44 is a short isoform of p53 that has been proved to orchestrate p53 
functions. p44 lacks the first transactivation domain (TAD), but retains the 
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second TAD and all the p53 functional domains (Khoury and Bourdon, 
2011). p44, thanks to its intact oligomerization domain, has the ability to 
form oligomers with p53, determining its localization and fine-tuning its 
transcriptional activity: (i) endoplasmic reticulum (ER) stress promotes the 
formation of p44/p53 oligomers leading to G2 arrest of the cell cycle that 
cannot be induced by p53 alone (Bourougaa et al., 2010); (ii) the human 
p44 ortholog accumulates in response to genotoxic stress enhancing p21 
expression (Powell et al., 2008); (iii) p44 is responsible for the 
downregulation of a specific mitotic signature of ~200 G2/M transition 
genes in response to OS. Downregulation of these genes is p53/p66Shc-
dependent and enhanced when p44 is overexpressed (Gambino et al., 
2013).  
Interestingly, p44 is involved in modulating p53 functions not only in 
response to stresses, but also in aging. The Tgp44 mouse overexpresses the 
p44 isoform and maintains unaltered full-length p53 expression. These mice 
show premature signs of aging: as early as 4-month old, they show 
osteoporosis, kyphosis, infertility and reduced body size, and die within the 
first year of age, without developing cancer (Maier et al., 2004). These 
findings show a correlation between OS response and aging, being both p44 
and p66Shc two aging proteins involved in promoting cell cycle arrest upon 
OS.  
As for p66Shc, our aim is to take advantage of N. furzeri to investigate the 
mechanisms through which p44 orchestrates p53 functions in determining 
stress response and aging processes. In zebrafish, the p44 isoform is 
produced by an alternative splicing mechanism, contrary to mammals, 
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where p44 is produced by alternative initiation of translation (Davidson et 
al., 2010). We identified the putative p44 ortholog by sequence analysis of 
the N. furzeri p53 genomic locus. The mechanism we propose for p44 
production in N. furzeri is the same as zebrafish: the alternative splicing of 
p53 intron 2. The utilization of an intronic ATG, in-frame with the 
downstream p53 exons, leads to the production of a N-terminally truncated 
isoform of p53, where the first TAD is lost. We demonstrated that the full-
length cDNA sequence of the putative Np44 ortholog is expressed at low 
levels in several N. furzeri adult tissues (brain, heart, intestine and testes; 
Figure 1.A).  
Our preliminary results of heterologous complementation experiments 
in p53-/- MEFs reconstituted with either Np53 or Np44 show that: (i) both 
Np53 and Np44 are able to enter the mammalian transcriptional regulation 
machinery; (ii) Np53 induces cell senescence upon OS and genotoxic stress 
(GS), but also at basal conditions; (iii) Np53 alone is not able to 
downregulate the 31 G2/M genes but it induces the upregulation of p21 
upon both OS and GS; (iv) Np44 alone is able to induce the downregulation 
of G2/M genes only upon OS and a mild upregulation of p21 upon GS 
(Figure 3). These data suggest that future experiments have to be planned 
in order to modulate Np53 expression in p53-/- MEFs: in fact, Np53 is able to 
induce cell cycle arrest also at basal conditions. This makes the other results 
difficult to interpret. On the other hand, Np44 is able to induce the 
downregulation of G2/M genes only upon OS. In mammals, p44 is 
implicated in OS response: this fact suggests that Np44 might recapitulate 
mammalian p44 functions in orchestrating the p53-dependent 
transcriptional response to different kind of stressors. In vivo experiments 
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in N. furzeri are necessary to clarify whether Np44 is indeed activated by OS 
and, for example, in which tissues is preferentially expressed upon OS and 
at basal conditions. Moreover, the alternative splicing mechanism through 
which Np44 is produced gives the chance to selectively knock-out Np44 in 
this organism, without interfering with Np53 sequence. Indeed, it has been 
observed in mice that a point mutation introduced to mutagenize the p44 
ATG leads to a dramatic reduction of the p53 mRNA levels due to its 
instability (Melis et al., 2011). Considering this, a genetic model of selective 
p44 ablation is not feasible in mice. The production of a p44-/- model in N. 
furzeri will reveal how the p44 isoform modulates stress response in vivo. 
Finally, being N. furzeri the shortest-living vertebrate model organism, a 
p44-/- model will be also fundamental to deeply investigate the role of p44 
in aging and lifespan modulation. 
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Regulation of p66Shc/p52Shc and p53/p44 
expression in the developing zebrafish embryo 
p66Shc is involved in oxidative stress (OS) response and aging, while its 
role in in embryonic development has never been investigated. However, 
transcriptional response to OS is involved in orchestrating the balance 
between proliferation and differentiation during embryogenesis. Moreover, 
p53 and its short isoform p44 (the partners that cooperate with p66Shc in 
the transcriptional network induced by OS) play a role in early mouse 
embryogenesis. Thus, we asked whether p66Shc takes part to developmental 
processes, taking advantage of Danio rerio (zebrafish). Whole-mount in situ 
hybridization of p66Shc and qPCR analyses show that p66Shc expression is 
spatially restricted to the embryonic cephalic area and it is regulated over 
time. 
1. Materials and Methods 
1.1  Danio rerio maintenance 
Adult zebrafish are maintained in a commercial system (Aquatic Habitat) 
with a density of 0.2L per adult zebrafish; water temperature is set at 
28.5°C, pH at 7 and conductivity at 500µS. The circadian rhythm imposed is 
14 hours of light and 10 hours of darkness. Fish are fed three times a day 
with living brine shrimps and standard dry food (MBK Installations). Juvenile 
zebrafish (from 6 days to three weeks) are fed with dry brine shrimps (JBL) 
and standard dry food (Zeigler). Zebrafish embryos are maintained at 28°C 
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in “E3” water (50mM NaCl, 0.17mMKCl, 0.33mM CaCl, 0.33mM MgSO4, 
0.05% methylene blue).  
1.2  Synthesis of Digoxigenin (DIG)-labelled RNA probes for 
zebrafish p66Shc, p52Shc, p53 and p44. 
Total RNA was extracted from a pool of 50 48hpf zebrafish embryos 
with Qiazol Reagent (QIAGEN) according to the manufacturer instructions. 
After extraction, 30µg of total RNA were treated with 6U of TURBO DNase 
(Ambion) for 30’ at 37°C and then column purified (Quick-RNA MiniPrep kit, 
Zymo Research). 1µg of total RNA was then retrotranscribed 1h at 42°C for 
cDNA synthesis using 0.5µg of oligodT (Invitrogen), 160U of ImProm-II 
Reverse Transcriptase (Promega), 3mM MgCl2, 0.3mM dNTPs and 20U of 
RNAse Inhibitor (NEB).  About 100ng of cDNA were used for RT-PCR to 
amplify template sequences of p66Shc, p52Shc, p53 and p44 with the primers 
listed in the table below. A 30-cycle touchdown RT-PCR was run as follows: 
2U of Phusion High Fidelity DNA Polymerase (NEB), 0.2mM dNTPs and 
0.5µM each primer with an annealing temperature decreasing from 64°C to 
57°C. PCR products of the expected length were then extracted from 0.8% 
agarose gel using QIAquick Gel Extraction Kit (QIAGEN), according to 
manufacturer instructions. Addition of 3’-A overhangs to gel-extracted PCR 
products was performed using 1 U of Taq Polymerase (QIAGEN) 30’ at 72°C. 
Then PCR amplicons were ligated at 16°C overnight into the pGEM-T easy 
vector (Promega), which harbours both SP6 and T7 promoter sequences. 
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Ligation reactions were used to transform TOP10 competent cells 
(Thermo Fisher Scientific) according to the manufacturer instructions. 
Plasmid DNA from 2ml of overnight mini-cultures was extracted with 
Nucleospin Plasmid Kit (Macherey-Nagel) and sequenced by Sanger 
sequencing. Sequences were then analysed with Chromas lite software 
(Technelysium) to determine insert orientation. 5µg of plasmid DNA for 
each construct was then linearized 4h at 37°C with NcoI or SalI restriction 
enzymes (New England Biolabs). Digested plasmid DNA was then checked 
for complete linearization on agarose gel and purified with QIAquick PCR 
purification kit (QIAGEN).  
For each target mRNA, both the antisense and the sense probe were 
produced. In vitro transcription was performed 2h at 37°C as follows: 1µg of 
each linearized plasmid as template, 10mM DTT (Promega), DIG-RNA 
Labelling mix (Roche), 30U of T7 or SP6 RNA polymerase (Promega). In vitro 
transcription reactions were then DNAse treated (15’ at 37°C with 4U of 
Turbo DNAse, Ambion), and precipitated with ammonium acetate/ethanol. 
RNA DIG-labelled probes were then checked for integrity on agarose gel.  
 
 
Probe Forward primer Reverse primer Ampl. length 
Zp66Shc GTATGACAACAGCAGAAAACTTG CTGTGGGGGACGAGGA 683bp 
Zp52Shc GGCAGAACCGAAGAGAAAAG ATATACCTGACAGTGTAGGAGAC 343bp 
Zp53 GGTCGGCAAAATCAATTCTTG GGTCGGCAAAATCAATTCTTG 217bp 
Zp44 ATGTCAGGTTGCTATAATGTACC CGATCCCGGCAAGTACTC 221bp 
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1.3  Whole-mount in situ hybridization on zebrafish embryos 
Zebrafish embryos at early developmental stages were manually 
dechorionated and, after 24hpf, they were treated with 0.0003% 
phenylthiourea to avoid pigmentation.  Embryos were fixed 2h at room 
temperature with 4% paraformaldehyde (Sigma-Aldrich) in PBS. Fixed 
embryos were then dehydrated in 25%-50%-75% methanol/PBS solutions 
and conserved in methanol at -20°C.  
For whole-mount in situ hybridization, embryos were rehydrated in 
75%-50%-25% methanol/PBS solutions and then washed four times 5’ in 
PBS. 
Whole-mount in situ hybridization was performed as described by 
Thisse and Thisse, 2008. Briefly, after rehydration, embryos were 
permeabilized by digestion with 10µg/mL proteinase K in PBT (PBS + 1% 
Tween-20) and post-fixed in 4% PFA for 20’ at room temperature. Embryos 
were then washed in PBS and incubated for 3h at 65°C in hybridization mix. 
Following pre-hybridization, embryos were incubated over-night at 65°C in 
hybridization mix containing 1ng/µL sense or antisense probe. After 
washing in hybridization mix/SSC and PBT, embryos were incubated in 
blocking solution (2% sheep serum + 2% BSA in PBT) 1h at room 
temperature and then incubated over-night at 4°C with alkaline-
phosphatase conjugated anti-digoxigenin antibody (Roche, diluted 1:3000 
in blocking solution).  
Embryos were then extensively washed in PBT and stained with 
NBT/BCIP (Promega), diluted in staining buffer (100mM Tris-HCl pH 9.5, 
50mM MgCl2, 100mM NaCl, 0.1% Tween-20) following manufacturer 
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instructions. Images of stained embryos were acquired on a Leica M205 FA 
microscope with a Leica DFC 450C camera.  
1.4 Real-Time RT-PCR of p66Shc and p52Shc  
Total RNA was extracted from 3 pools of 30-100 zebrafish embryos at 
different developmental stages with Qiazol Reagen (QIAGEN), according to 
manufacturer instructions. After extraction, 30µg of total RNA were treated 
with 6U of TURBO DNase (Ambion) for 30’ at 37°C and then column purified 
(Quick-RNA MiniPrep kit, Zymo Research). 1µg of total RNA was then 
retrotranscribed 1h at 42°C for cDNA synthesis using 0.5µg of a primer mix 
consisting in oligodT and random primers (Invitrogen) in 3:1 ratio, 160U of 
ImProm-II Reverse Transcriptase (Promega), 3mM MgCl2, 0.3mM dNTPs 
and 20U of RNAse Inhibitor (NEB).  A two-step qPCR was run using ~100ng 
of cDNA as template, 0.2µM each primer and Fast SYBR Green Master Mix 
2X (Applied Biosystems) in a total volume of 20µl. qPCR was run as follows: 
2’ at 95°C, then 3’’ at 95°C and 30’’ at 60°C for 40 cycles. p66Shc and p52Shc 
were discriminated each other using specific couples of primers, listed 
below. eEF1A-1a was used as housekeeping gene. Data are presented as 
the mean ± standard error. Gastrulation stage was used as internal 
calibrator.  
Gene Forward primer Reverse primer Ampl. length 
Zp66Shc CACCACCTTATGCTCCTTCTTC TTCCGAGGACTCTCCCAAA 139bp 
Zp52Shc AGTGTCTTCCAATGGAGTATGTG CATGCCGTGTCCACTCATC 105bp 
ZEF1a CGGTACTACTCTTCTTGATGCC CAGGCTTGAGGACACCAG 152bp 
Unravelling the p53/p66Shc pathway in vivo  
 
146 
 
2. Results 
2.1  p66Shc mRNA levels increase at later developmental 
stages 
It has been shown in zebrafish that p52Shc, the shorter isoform of the 
shc1 gene, is involved in embryonic angiogenesis (Sweet et al., 2012). On 
the contrary, the role of the p66Shc isoform is still unknown. Therefore, to 
gain new insights on p66Shc functions, we investigated for the first time how 
p66Shc, the longest isoform of shc1, is regulated over time during zebrafish 
development. We extracted total RNA from three pools of zebrafish 
embryos at different developmental stages and we quantified mRNA levels 
of p66Shc through Real-Time RT-PCR. We considered: 50% epiboly (when the 
zebrafish organiser is visible), early somitogenesis (1-3 somites), late 
somitogenesis (15-18 somites), 24hpf (hours post fertilization), 48hpf, 
72hpf (when organogenesis is complete and the embryo hatches), 96hpf 
and 120hpf (Kimmel et al., 1995). Gastrulation stage was used as internal 
calibrator. We also discriminated p66Shc from p52Shc, thanks to the design of 
primers that specifically amplify p66Shc or p52Shc: primers for p66Shc are 
designed on the sequence that is unique to this isoform and previously 
determined (Priami et al., 2015), while primers for p52Shc are designed on 
the 5’UTR specific to this isoform and on exon 2 of its coding sequence 
(Figure 1). We used eEF1α-1a (eukaryotic elongation factor 1alpha-1a) as 
housekeeping gene, as its expression levels are stable during zebrafish 
development (McCurley and Callard, 2008). We observed that (i) mRNA 
levels of p66Shc are very low at early developmental stages, then they 
dramatically increase, reaching a peak at 48hpf-72hpf; (ii) mRNA levels of 
p52Shc are stable over time (Figure 2).  
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Figure 1. The shc1 locus in zebrafish. p66Shc has a unique N-terminal domain and 
shares its amino-acidic sequence with p52Shc from exon 2. a) The p52Shc probe 
(blue box) is designed on p52Shc 5’UTR/exon 2, to exclude a non-specific 
hybridization with p66Shc mRNA. qPCR primers for p52Shc (blue arrows) are also 
designed to exclude amplification of p66Shc cDNA. b) The p66Shc probe (green box) 
and p66Shc qPCR primers (green arrows) are designed on the shc1 sequence 
unique to p66Shc to exclude non-specific hybridization with p52Shc mRNA and 
amplification of p52Shc cDNA.  
Figure 2. Expression regulation of p66Shc and p52Shc in zebrafish development. 
Log2(Fold changes) of p66Shc and p52Shc at different developmental stages (Ga: 
gastrulation; TB: early somitogenesis; So: late somitogenesis; 24hpf; 48hpf; 72hpf; 
96hpf; 120hpf). Real-Time RT-PCR was performed with specific couples of primers 
to discriminate the two isoforms (Figure 1). p66Shc expression reaches a peak 
between 48hpf and 72hpf, then slightly decreases. p52Shc expression is stable 
during development. Data are present as the mean ± standard error of three 
biological replicates. Ef1α-1a was used as housekeeping gene and gastrulation 
stage as internal calibrator. 
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2.2 p66Shc expression is restricted to the cephalic area in 
zebrafish development 
We asked whether p66Shc expression is not only temporally, but also 
spatially regulated in zebrafish development. In order to determine p66Shc 
expression domain and to distinguish it from p52Shc, we designed specific 
probes to discriminate the two isoforms through in situ hybridization: the 
probe for p66Shc is designed on the sequence unique to p66Shc and the 
probe for p52Shc is designed on 5’UTR unique to this isoform and on the first 
exon of its coding sequence (Figure 1). We determined, through in situ 
hybridization, p66Shc expression domain at five developmental stages: late 
somitogenesis (15-18 somites), 24hpf, 48hpf, 72hpf and 96hpf. We found 
that p66Shc expression is ubiquitous in the 15-18 somite-embryo, being 
more concentrated in the eye and the trigeminal placodes (recognizable as 
the two lateral patches at the lateral edge of the neuroepithelium) that will 
originate the trigeminal ganglia (Andermann et al., 2002). At 24hpf, p66Shc 
expression is still ubiquitous, but concentrated in the brain, in the 
trigeminal placodes and in Rohon-Beard neurons, transient 
mechanoreceptors located dorsally in the spinal cord, that undergo 
programmed cell death after 24hpf (Reyes et al., 2004; Figure 3.A). At 
48hpf, p66Shc expression is localized (i) in the brain and in particular in the 
optic tectum, (ii) in the ciliary marginal zone of the retina, where retinal 
stem cells and retinal progenitor cells are located (Moshiri et al., 2004) and 
(iii) in the trigeminal ganglion, now positioned ventrally to the brain 
between the eyes and the otic vescicles, where the nuclei of the touch 
sensory neurons of the fifth cranial nerve are located (Kimmel et al., 1995; 
Figure 3.B). 
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Figure 3. p66Shc expression pattern in zebrafish development. p66Shc expression is 
ubiquitously distributed in late somitogenesis and at 24hpf (A), being more 
concentrated in the eye and the trigeminal placodes (red arrows). At 24hpf it is 
also evident in the Rohon-Beard neurons. At 48hpf (B) p66Shc is expressed in the 
brain and in particular in the optic tectum, in the ciliary marginal zone of the 
retina, and in the trigeminal ganglion (red arrows). At 72hpf (C) and 96hpf (D), 
p66Shc expression is still restricted to the cephalic area and concentrated in the 
optic tectum, in the ciliary marginal zone of the retina and in the trigeminal 
ganglion (red arrows). 
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At 72hpf and 96hpf, p66Shc expression is still restricted to the cephalic 
area and concentrated in the optic tectum, in the ciliary marginal zone of 
the retina and in the trigeminal ganglion (Figure 3.C/D.). We also analysed 
p52Shc expression at 24hpf and 48hpf through in situ hybridization and we 
found that, at least at these developmental stages, p52Shc expression is not 
spatially restricted, being ubiquitously distributed in the embryo (Figure 4). 
Figure 4. p66Shc and p52Shc expression patterns. Through whole-mount in situ 
hybridization we discriminated the expression patterns of the two isoforms of the 
shc1 gene. At 24hpf (A) and 48hpf (B), p52Shc is ubiquitously expressed, contrary 
to p66Shc.  
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2.3 p53 and p44 share the same expression pattern. 
p44 is a splicing isoform of p53 that is mostly expressed in the early 
mammalian embryo, when it is involved in the preservation of pluripotency: 
for this reason, it has been described as an embryonic isoform of p53 
(Ungewitter and Scrable, 2010). We decided to investigate whether p44 and 
p53 have different expression domains in the developing zebrafish embryo. 
To address this question, we generated specific probes for p53 and p44: we 
took advantage of the sequence that is unique to p44 to design a short 
probe on the intron 2/exon 3-4 of p53 locus, while the p53 probe was 
designed across 5’UTR/exon 4 (Figure 5). We used this assay to discriminate 
p53 expression domains from p44 through whole-mount in situ 
hybridization. In the 48hpf zebrafish embryo, p53 resulted expressed (i) in 
the midbrain-hindbrain boundary, an area of persistent cell proliferation 
until 72hpf (Wulliman and Knipp, 2000); (ii) in the retina; (iii) in the fin buds, 
another area of active cell proliferation (Nomura et al., 2006); (iv) in the 
pharyngeal arches, which will form gills and jaws; (v) in the otic vesicles and 
(vi) in the hatching glands. At the same developmental stage, whole-mount 
in situ hybridization with the p44-specific probe shows that this isoform 
shares the same expression pattern of p53 (Figure 6).  
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Figure 5. The p53 locus in zebrafish. p44 is a splicing isoform of p53.  a) The p53 
probe (blue box) is designed on p53 5’UTR and on exons 2-4 to exclude a non-
specific hybridization with p44 mRNA. b) The p44 probe (green box) is designed 
on the p53 sequence unique to p44 and on exons 3-4 to exclude non-specific 
hybridization with p53 mRNA.  
 
Figure 6. p53 and p44 expression patterns at 48hpf. Whole-mount in situ 
hybridization of p53 and p44 probes on 48hpf zebrafish embryos shows that these 
isoforms share the same expression domains. p53 and p44 are both expressed (i) 
in the midbrain-hindbrain boundary; (ii) in the retina; (iii) in the fin buds; (iv) in 
the pharyngeal arches; (v) in the otic vesicles and (vi) in the hatching glands. 
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3. Discussion 
p66Shc is the longest isoform encoded by the shc1 locus. The shortest 
isoforms, p52Shc and p46Shc are involved in Ras signalling. These two 
isoforms are phosphorylated by active tyrosine kinase receptors and drive 
the MAPK (Mitogen-Activated Protein Kinase) cascade (Pelicci et al., 1992). 
The third isoform, p66Shc, is translated from a different mRNA. p66Shc 
contains the entire p52Shc/p46Shc sequence plus an additional amino-
terminal region (Ventura et al., 2002). p66Shc is not involved in Ras 
signalling, being unable to activate the MAPK cascade. Therefore, p66Shc, 
contrary to p52Shc/p46Shc does not contribute to stimulate proliferation 
(Migliaccio et al., 1997). p66Shc is involved in oxidative stress response (OS): 
OS activates p66Shc and promotes apoptosis (Giorgio et al., 2005). The 
p66Shc-/- mouse model, generated in 1999, is a genetic model of healthy 
aging. It has been demonstrated that the deletion of p66Shc improves 
general health in the aging mouse and that it is associated with an 
elongation in lifespan, although this datum is still controversial (Migliaccio 
et al., 1999; Ramsey et al., 2014). The fact that the ablation of p66Shc is 
associated with an amelioration of the aging phenotype in laboratory mice 
and in mouse models of human aging-associated diseases implies that 
p66Shc has been evolutionary selected for its positive functions exerted in 
development and/or reproductive phase of life. On the other hand, it is 
evident as well that p66Shc is not necessary in embryogenesis, because 
p66Shc-/- mice are viable and p66Shc-/- embryos are not counterselected 
during gestation. For these reasons, few attentions have been focused in 
understanding the role of p66Shc in development. Although, differences in 
phenotypic effects obtained with gene knockdown and mutagenesis 
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highlighted that mechanisms of genetic compensation may explain why 
deleterious mutations have sometimes no morphological effects, while 
gene knockdown leads to developmental alterations: mutations in the 
genome can trigger up- or downregulation of genes related to the ablated 
one (Rossi et al., 2015). This means that the ablated gene has not to be 
considered “necessary”, but, nevertheless, it is “functional”. This might be 
the case of p66Shc, given that, as it was explained in Part I, it belongs to a 
family of genes. In fact, there are some evidence suggesting a role for p66Shc 
in neurogenesis. The expression regulation of the three isoforms of the 
shcA gene was investigated in 1997 through in situ hybridization in the 
brain of the developing mouse: all the three isoforms are exclusively 
expressed within the ventricular zone, the area were immature neuroblasts 
proliferate, being p66Shc the less represented isoform. Considering that 
p66Shc, contrary to the other isoforms, is not involved in proliferation, these 
findings lead to the intriguing hypothesis that p66Shc, in concert with 
p52Shc/p46Shc, has the role of orchestrating cell fate in neurogenesis (Conti 
et al., 1997). According with these observations, it has been found that in 
human and murine embryonic stem cells the overexpression of p66Shc 
anticipates the loss of pluripotency and induces the acquisition of a 
neuronal fate (Papadimou et al., 2009). These data suggest that p66Shc 
might have a role in development and in particular in neuronal 
differentiation.  
In zebrafish, it has been shown that specific knockdown of p52Shc/p46Shc 
leads to defects of intersegmental vessel sprouting angiogenesis (Sweet et 
al., 2012). The aging-associated isoform of Shc, p66Shc, has never been 
investigated in fish. Through bioinformatic analysis it has emerged that the 
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shc locus in zebrafish shows conservation with mammals: in Ensemble 
genome browser is present a protein coding putative transcript for p66Shc 
(ENSDART00000098400). Ensemble prediction was used as a reference for 
molecular cloning of the p66Shc full length cDNA, demonstrating for the first 
time that this isoform is actually expressed in zebrafish and that the 
functional domains present in the N-terminal sequence unique to p66Shc are 
conserved between zebrafish and mammals (Priami et al., 2015).  
Our Real-Time RT-PCR and whole-mount in situ hybridization analyses on 
zebrafish embryos at different developmental stages show that the shorter 
and the longest isoforms of shc1 are differently regulated in zebrafish 
development. p52Shc behaves as a housekeeping gene, as it does not show a 
temporal regulation from gastrulation to the fifth day of development. Its 
expression pattern is ubiquitous at 24hpf and 48hpf: this data suggests that 
p52Shc, known for its role in MAPK signalling, might not have a role in tissue 
specification but in sustaining general cell proliferation. On the contrary, 
p66Shc is temporally regulated in zebrafish development: its mRNA levels are 
low at early developmental stages and increase at later stages, reaching a 
peak between 48hpf and 72hpf, during the organogenesis process, when 
areas of active cell proliferation become more and more restricted and the 
vast majority of cell types are differentiated (Kimmel et al., 1995). After 
72hpf p66Shc expression slightly decreases. Whole-mount in situ 
hybridization of p66Shc at different developmental stages, from late 
somitogenesis to 96hpf, shows that p66Shc expression is concentrated, until 
24hpf, in neural crest-derived structures, such as the trigeminal placodes 
and Rohon-Beard neurons, transient mechanoreceptors located dorsally in 
the spinal cord, that undergo programmed cell death after 24hpf (Reyes et 
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al., 2004; Figure 3). After 48hpf, interestingly, p66Shc is expressed only in the 
cephalic area: (i) in the brain and in particular in the optic tectum, where 
neural progenitors are located (Ito et al., 2010); (ii) in the ciliary marginal 
zone of the retina, where retinal stem cells and retinal progenitor cells are 
located (Moshiri et al., 2004) and (iii) in the trigeminal ganglion, now 
positioned ventrally to the brain between the eyes and the otic vesicles, 
where the nuclei of the touch-sensory neurons of the trigeminal or fifth 
cranial nerve are located (Kimmel et al., 1995; Figure 4). Our data suggests 
that p66Shc might be involved in brain development and in the specification 
of the neural crest-derived structures where it appears to be strongly 
expressed (trigeminal ganglia and Rohon-Beard neurons). This hypothesis is 
supported by the fact that (i) also in mammals, p66Shc is localized in the 
proliferating area of the developing brain, the ventricular zone (Conti et al., 
1997), (ii) in human and murine embryonic stem cells, the overexpression 
of p66Shc induces the acquisition of a neuronal fate (Papadimou et al., 
2009). Experiments of double in situ hybridization of p66Shc together with 
neural stem cell markers (e.g. musashi-1; Sakakibara et al., 1996) and neural 
crest markers (e.g. islet-1; Inoue et al., 1994) will confirm that p66Shc is 
localized in these cell types.  
In this study, we also analysed p53 and p44 expression patterns during 
zebrafish development through in situ hybridization. p44 is a N-terminally 
truncated isoform that lacks the first transcription activation domain (TAD), 
but retains the second TAD and all the p53 functional domains, maintaining 
the ability to form oligomers with the canonical p53 protein. In mammals, it 
has been shown that the p44 isoform determines p53 functions: it is known 
that p44, thanks to its intact oligomerization domain, has the ability to form 
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oligomers with p53, determining its localization and fine-tuning its 
transcriptional activity, in particular in stress response (Ghosh et al., 2004; 
Bourougaa et al., 2010; Powell et al., 2008). p44 plays also an important 
role in development: p44 has been considered an embryonic isoform of 
p53, whose expression is high in pluripotent stem cells and decrease as 
differentiation occurs. The main function of p44 in the early stages of 
embryogenesis is to suppress p53 activity by preventing the trans-
suppression of factors such as Nanog and IGF-1R, to preserve pluripotency. 
When the levels of p44 decrease, the negative regulation of p53 decreases 
as well and embryonic stem cells begin to differentiate (Ungewitter and 
Scrable, 2010).  
The existence of a p44 ortholog in zebrafish has been shown by Davidson 
and colleagues in 2010: the microinjection of p44 mRNA in wild-type 
embryos is associated with severe developmental abnormalities. On the 
contrary, microinjection of p44 mRNA in p53M214K embryos does not lead to 
any morphological alteration, suggesting that, as previously shown in 
mammals, the p44 isoform acts only in cooperation with FLp53. Moreover, 
p44 overexpression is evident after treatment with ionizing radiation: as in 
mammals, in zebrafish this isoform is overexpressed in response to stress 
(Davidson et al., 2010). This work supports the idea that zebrafish p44 
recapitulates mammalian p44 functions, but do not investigate the role of 
p44 in physiological conditions.  
Here we show that p44 and p53 share the same expression patterns in 
48hpf embryos. Both the isoforms are expressed: (i) in the midbrain-
hindbrain boundary, an area of persistent cell proliferation until 72hpf 
(Wulliman and Knipp, 2000); (ii) in the retina; (iii) in the fin buds, another 
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area of active cell proliferation (Nomura et al., 2006); (iv) in the pharyngeal 
arches, which will form gills and jaws; (v) in the otic vesicles and (vi) in the 
hatching glands. It is not surprising that p53 and p44 are expressed in the 
same areas, considering that (i) p44 has been described as a splicing 
isoform of p53 (Davidson et al., 2010) and (ii) it is demonstrated that p44 
has to interact with p53 to exert its functions (Maier et al., 2004; 
Ungewitter and Scrable, 2010). Interestingly, both p53 and p44 are 
expressed in proliferating areas of the developing zebrafish embryo: this 
observation is consistent with previous data showing that p44 and p53 
cooperate during embryogenesis in maintaining the balance between 
proliferation and differentiation (Ungewitter and Scrable, 2010). We 
recently generated a p44-/- line in zebrafish in which p53 expression is 
unaltered: the p44-/- line will be useful to elucidate the role of p44 in 
development, under normal and stressed conditions. 
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